<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE chapter PUBLIC "-//ES//DTD book DTD version 5.5.0//EN//XML" "book550.dtd" [<!ENTITY f007-001-9780702070280 SYSTEM "f007-001-9780702070280" NDATA IMAGE><!ENTITY f007-002-9780702070280 SYSTEM "f007-002-9780702070280" NDATA IMAGE><!ENTITY f007-003-9780702070280 SYSTEM "f007-003-9780702070280" NDATA IMAGE><!ENTITY f007-004-9780702070280 SYSTEM "f007-004-9780702070280" NDATA IMAGE><!ENTITY f007-005-9780702070280 SYSTEM "f007-005-9780702070280" NDATA IMAGE><!ENTITY f007-006-9780702070280 SYSTEM "f007-006-9780702070280" NDATA IMAGE><!ENTITY icon01-9780702070280 SYSTEM "icon01-9780702070280" NDATA IMAGE><!ENTITY icon02-9780702070280 SYSTEM "icon02-9780702070280" NDATA IMAGE><!ENTITY u007-001-9780702070280 SYSTEM "u007-001-9780702070280" NDATA IMAGE><!ENTITY u007-002-9780702070280 SYSTEM "u007-002-9780702070280" NDATA IMAGE><!ENTITY u007-003-9780702070280 SYSTEM "u007-003-9780702070280" NDATA IMAGE>]><chapter docsubtype="chp" id="c00007" version="5.5" xml:lang="en" xmlns="http://www.elsevier.com/xml/bk/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink"><info><ce:pii>B978-0-7020-7028-0.00007-X</ce:pii><ce:doi>10.1016/B978-0-7020-7028-0.00007-X</ce:doi><ce:isbn>978-0-7020-7028-0</ce:isbn><ce:copyright type="full-transfer" year="2018">Elsevier Ltd</ce:copyright></info><ce:floats><ce:figure id="f0025"><ce:label>Fig. 7.1</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0020" role="title">Methaemoglobinaemia.</ce:simple-para></ce:caption><ce:alt-text id="atte0010" role="short">Fig. 7.1</ce:alt-text><ce:link id="ln0050" locator="f007-001-9780702070280" xlink:href="pii:B978070207028000007X/f007-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 7.2</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0035" role="title">Paracetamol treatment nomogram (UK).</ce:simple-para><ce:simple-para id="sp9000" role="caption">Above the treatment line, benefits of treatment outweigh risk. Below it, risks of treatment outweigh benefits.</ce:simple-para></ce:caption><ce:alt-text id="atte0015" role="short">Fig. 7.2</ce:alt-text><ce:link id="ln0075" locator="f007-002-9780702070280" xlink:href="pii:B978070207028000007X/f007-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0035"><ce:label>Fig. 7.3</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0045" role="title">ECG in severe tricyclic antidepressant poisoning.</ce:simple-para><ce:simple-para id="sp0050" role="caption">This rhythm strip shows a broad QRS complex due to impaired conduction.</ce:simple-para></ce:caption><ce:alt-text id="atte0020" role="short">Fig. 7.3</ce:alt-text><ce:link id="ln0085" locator="f007-003-9780702070280" xlink:href="pii:B978070207028000007X/f007-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0040"><ce:label>Fig. 7.4</ce:label><ce:caption id="ca0035"><ce:simple-para id="sp0060" role="title">Abdominal X-ray of a body packer showing multiple drug-filled condoms.</ce:simple-para></ce:caption><ce:alt-text id="atte0025" role="short">Fig. 7.4</ce:alt-text><ce:link id="ln0100" locator="f007-004-9780702070280" xlink:href="pii:B978070207028000007X/f007-004-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0045"><ce:label>Fig. 7.5</ce:label><ce:caption id="ca0040"><ce:simple-para id="sp0065" role="title">Mechanism of toxicity of organophosphorus compounds and treatment with oxime.</ce:simple-para></ce:caption><ce:alt-text id="atte0030" role="short">Fig. 7.5</ce:alt-text><ce:link id="ln0110" locator="f007-005-9780702070280" xlink:href="pii:B978070207028000007X/f007-005-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0050"><ce:label>Fig. 7.6</ce:label><ce:caption id="ca0045"><ce:simple-para id="sp0070" role="title">Metabolism of methanol and ethylene glycol.</ce:simple-para></ce:caption><ce:alt-text id="atte0035" role="short">Fig. 7.6</ce:alt-text><ce:link id="ln0120" locator="f007-006-9780702070280" xlink:href="pii:B978070207028000007X/f007-006-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:textbox id="b0015" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0025" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0040" role="short">Image 1</ce:alt-text></ce:inline-figure>7.1</ce:label><ce:alt-text id="atte0045" role="short">7.1</ce:alt-text><ce:textbox-head><ce:title id="tit0020">Important substances involved in poisoning</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0015"><ce:section-title id="st0015">In the UK</ce:section-title><ce:para id="p0235"><ce:list id="ulist0040"><ce:list-item id="u0225"><ce:label>•</ce:label><ce:para id="p0240">Analgesics: paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs)</ce:para></ce:list-item><ce:list-item id="u0230"><ce:label>•</ce:label><ce:para id="p0245">Antidepressants: tricyclic antidepressants (TCAs), selective serotonin re-uptake inhibitors (SSRIs) and lithium</ce:para></ce:list-item><ce:list-item id="u0235"><ce:label>•</ce:label><ce:para id="p0250">Cardiovascular agents: β-blockers, calcium channel blockers and cardiac glycosides</ce:para></ce:list-item><ce:list-item id="u0240"><ce:label>•</ce:label><ce:para id="p0255">Drugs of misuse: depressants (e.g. opiates, benzodiazepines), stimulants and entactogens (e.g. amphetamines, MDMA, mephedrone, cocaine), hallucinogens (e.g. cannabis, synthetic cannabinoid receptor agonists, LSD)</ce:para></ce:list-item><ce:list-item id="u0245"><ce:label>•</ce:label><ce:para id="p0260">Carbon monoxide</ce:para></ce:list-item><ce:list-item id="u0250"><ce:label>•</ce:label><ce:para id="p0265">Alcohol</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0020"><ce:section-title id="st0020">In South and South-east Asia</ce:section-title><ce:para id="p0270"><ce:list id="ulist0045"><ce:list-item id="u0255"><ce:label>•</ce:label><ce:para id="p0275">Organophosphorus and carbamate insecticides</ce:para></ce:list-item><ce:list-item id="u0260"><ce:label>•</ce:label><ce:para id="p0280">Aluminium and zinc phosphide</ce:para></ce:list-item><ce:list-item id="u0265"><ce:label>•</ce:label><ce:para id="p0285">Oleander</ce:para></ce:list-item><ce:list-item id="u0270"><ce:label>•</ce:label><ce:para id="p0290">Corrosives</ce:para></ce:list-item><ce:list-item id="u0275"><ce:label>•</ce:label><ce:para id="p0295">Snake venoms (<ce:intra-ref id="ii0010" xlink:href="pii:B978-0-7020-7028-0.00008-1#c00008">Ch. 8</ce:intra-ref>)</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0300">(LSD = lysergic acid diethylamide; MDMA = 3,4-methylene-dioxymethamphetamine, ecstasy)</ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0020" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0030" locator="icon02-9780702070280" xlink:href="pii:B978070207028000007X/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0050" role="short">Image 2</ce:alt-text></ce:inline-figure>7.2</ce:label><ce:alt-text id="atte0055" role="short">7.2</ce:alt-text><ce:textbox-head><ce:title id="tit0025">Poisoning in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0305"><ce:list id="ulist0050"><ce:list-item id="u0280"><ce:label>•</ce:label><ce:para id="p0310"><ce:bold>Aetiology</ce:bold>: may result from accidental poisoning (e.g. due to delirium or dementia) or drug toxicity as a consequence of impaired renal or hepatic function or drug interaction. Toxic prescription medicines are more likely to be available.</ce:para></ce:list-item><ce:list-item id="u0285"><ce:label>•</ce:label><ce:para id="p0315"><ce:bold>Psychiatric illness</ce:bold>: self-harm is less common than in younger adults but more frequently associated with depression and other psychiatric illness, as well as chronic illness and pain. There is a higher risk of subsequent suicide.</ce:para></ce:list-item><ce:list-item id="u0290"><ce:label>•</ce:label><ce:para id="p0320"><ce:bold>Severity of poisoning</ce:bold>: increased morbidity and mortality result from reduced renal and hepatic function, lower functional reserve, increased sensitivity to sedative agents and frequent comorbidity.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0025" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0035" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0060" role="short">Image 3</ce:alt-text></ce:inline-figure>7.3</ce:label><ce:alt-text id="atte0065" role="short">7.3</ce:alt-text><ce:textbox-head><ce:title id="tit0030">Substances of very low toxicity</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0370"><ce:list id="ulist0060"><ce:list-item id="u0310"><ce:label>•</ce:label><ce:para id="p0375">Writing/educational materials, e.g. pencil lead, crayons, chalk</ce:para></ce:list-item><ce:list-item id="u0315"><ce:label>•</ce:label><ce:para id="p0380">Decorating products, e.g. emulsion paint, wallpaper paste</ce:para></ce:list-item><ce:list-item id="u0320"><ce:label>•</ce:label><ce:para id="p0385">Cleaning/bathroom products (except dishwasher tablets and liquid laundry detergent capsules, which can be corrosive)</ce:para></ce:list-item><ce:list-item id="u0325"><ce:label>•</ce:label><ce:para id="p0390">Pharmaceuticals: oral contraceptives, most antibiotics (but not tetracyclines or antituberculous drugs), vitamins B, C and E, prednisolone, emollients and other skin creams, baby lotion</ce:para></ce:list-item><ce:list-item id="u0330"><ce:label>•</ce:label><ce:para id="p0395">Miscellaneous: plasticine, silica gel, most household plants, plant food, pet food, soil</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0030" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0040" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0070" role="short">Image 4</ce:alt-text></ce:inline-figure>7.4</ce:label><ce:alt-text id="atte0075" role="short">7.4</ce:alt-text><ce:textbox-head><ce:title id="tit0035">Causes of acidosis in the poisoned patient</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0415"><ce:display><ce:table frame="topbot" id="t0010"><ce:alt-text id="atte0080" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Cause</entry><entry align="left">Normal lactate<ce:cross-ref id="crf0220" refid="tn0010">*</ce:cross-ref></entry><entry align="left">High lactate</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Toxic</ce:bold></entry><entry align="left"><ce:list id="ulist0065"><ce:list-item id="u0335"><ce:para id="p0420">Salicylates</ce:para></ce:list-item><ce:list-item id="u0340"><ce:para id="p0425">Methanol</ce:para></ce:list-item><ce:list-item id="u0345"><ce:para id="p0430">Ethylene glycol</ce:para></ce:list-item><ce:list-item id="u0350"><ce:para id="p0435">Paraldehyde</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0070"><ce:list-item id="u0355"><ce:para id="p0440">Metformin</ce:para></ce:list-item><ce:list-item id="u0360"><ce:para id="p0445">Iron</ce:para></ce:list-item><ce:list-item id="u0365"><ce:para id="p0450">Cyanide</ce:para></ce:list-item><ce:list-item id="u0370"><ce:para id="p0455">Sodium valproate</ce:para></ce:list-item><ce:list-item id="u0375"><ce:para id="p0460">Carbon monoxide</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Other</ce:bold></entry><entry align="left"><ce:list id="ulist0075"><ce:list-item id="u0380"><ce:para id="p0465">Renal failure</ce:para></ce:list-item><ce:list-item id="u0385"><ce:para id="p0470">Ketoacidosis</ce:para></ce:list-item><ce:list-item id="u0390"><ce:para id="p0475">Severe diarrhoea</ce:para></ce:list-item></ce:list></entry><entry align="left">Shock</entry></row></tbody></tgroup><ce:table-footnote id="tn0010"><ce:label>*</ce:label><ce:note-para id="np0010">Unless circulatory shock is present, when it will be high in any case.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0035" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0045" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0085" role="short">Image 5</ce:alt-text></ce:inline-figure>7.5</ce:label><ce:alt-text id="atte0090" role="short">7.5</ce:alt-text><ce:textbox-head><ce:title id="tit0040">Anion and osmolar gaps in poisoning</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0480"><ce:display><ce:table frame="topbot" id="t0015"><ce:alt-text id="atte0095" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Anion gap</entry><entry align="left">Osmolar gap</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Calculation</ce:bold></entry><entry align="left">[Na<ce:sup loc="post">+</ce:sup> + K<ce:sup loc="post">+</ce:sup>] − [Cl<ce:sup loc="post">−</ce:sup> + HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup>]</entry><entry align="left">[Measured osmolality] − [(2 × Na) + Urea + Glucose]<ce:cross-ref id="crf0230" refid="tn0015"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry></row><row rowsep="1"><entry align="left"><ce:bold>Referencerange</ce:bold></entry><entry align="left">12–16 mmol/L</entry><entry align="left">&#x003C; 10</entry></row><row><entry align="left"><ce:bold>Common toxic causes of elevation</ce:bold><ce:cross-ref id="crf0235" refid="tn0020"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left"><ce:list id="ulist0080"><ce:list-item id="u0395"><ce:para id="p0485">Ethanol</ce:para></ce:list-item><ce:list-item id="u0400"><ce:para id="p0490">Ethylene glycol</ce:para></ce:list-item><ce:list-item id="u0405"><ce:para id="p0495">Methanol</ce:para></ce:list-item><ce:list-item id="u0410"><ce:para id="p0500">Salicylates</ce:para></ce:list-item><ce:list-item id="u0415"><ce:para id="p0505">Iron</ce:para></ce:list-item><ce:list-item id="u0420"><ce:para id="p0510">Cyanide</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0085"><ce:list-item id="u0425"><ce:para id="p0515">Ethanol</ce:para></ce:list-item><ce:list-item id="u0430"><ce:para id="p0520">Ethylene glycol</ce:para></ce:list-item><ce:list-item id="u0435"><ce:para id="p0525">Methanol</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0015"><ce:label>1</ce:label><ce:note-para id="np0015">All units should be in mmol/L, except osmolality, which should be in mOsmol/kg. For non-SI units, the corresponding formula is [Measured osmolality (mOsmol/kg)] − [(2 × Na (mEq/L)) + Urea/2.8 (mg/dL) + Glucose/18 (mg/dL)].</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0020"><ce:label>2</ce:label><ce:note-para id="np0020"><ce:intra-ref id="ii0055" xlink:href="pii:B978-0-7020-7028-0.00014-7#b0100">Box 14.19</ce:intra-ref> (<ce:intra-ref id="ii0060" xlink:href="pii:B978-0-7020-7028-0.00014-7#p2145">p. 365</ce:intra-ref>) gives non-toxic causes.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0040" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0055" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0100" role="short">Image 6</ce:alt-text></ce:inline-figure>7.6</ce:label><ce:alt-text id="atte0105" role="short">7.6</ce:alt-text><ce:textbox-head><ce:title id="tit0045">Substances poorly adsorbed by activated charcoal</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0555"><ce:display><ce:table frame="topbot" id="t0020"><ce:alt-text id="atte0110" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Medicines</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0090"><ce:list-item id="u0440"><ce:label>•</ce:label><ce:para id="p0560">Iron</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0095"><ce:list-item id="u0445"><ce:label>•</ce:label><ce:para id="p0565">Lithium</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Chemicals</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0100"><ce:list-item id="u0450"><ce:label>•</ce:label><ce:para id="p0570">Acids<ce:cross-ref id="crf0250" refid="tn0025">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0455"><ce:label>•</ce:label><ce:para id="p0575">Alkalis<ce:cross-ref id="crf0255" refid="tn0025">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0460"><ce:label>•</ce:label><ce:para id="p0580">Ethanol</ce:para></ce:list-item><ce:list-item id="u0465"><ce:label>•</ce:label><ce:para id="p0585">Ethylene glycol</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0105"><ce:list-item id="u0470"><ce:label>•</ce:label><ce:para id="p0590">Mercury</ce:para></ce:list-item><ce:list-item id="u0475"><ce:label>•</ce:label><ce:para id="p0595">Methanol</ce:para></ce:list-item><ce:list-item id="u0480"><ce:label>•</ce:label><ce:para id="p0600">Petroleum distillates<ce:cross-ref id="crf0260" refid="tn0025">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0025"><ce:label>*</ce:label><ce:note-para id="np0025">Gastric lavage contraindicated.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0045" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0060" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0115" role="short">Image 7</ce:alt-text></ce:inline-figure>7.7</ce:label><ce:alt-text id="atte0120" role="short">7.7</ce:alt-text><ce:textbox-head><ce:title id="tit0050">Poisons effectively eliminated by multiple doses of activated charcoal, haemodialysis or haemoperfusion</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0610"><ce:display><ce:table frame="topbot" id="t0025"><ce:alt-text id="atte0125" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Multiple doses of activated charcoal</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0110"><ce:list-item id="u0485"><ce:label>•</ce:label><ce:para id="p0615">Carbamazepine</ce:para></ce:list-item><ce:list-item id="u0490"><ce:label>•</ce:label><ce:para id="p0620">Dapsone</ce:para></ce:list-item><ce:list-item id="u0495"><ce:label>•</ce:label><ce:para id="p0625">Phenobarbital</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0115"><ce:list-item id="u0500"><ce:label>•</ce:label><ce:para id="p0630">Quinine</ce:para></ce:list-item><ce:list-item id="u0505"><ce:label>•</ce:label><ce:para id="p0635">Theophylline</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Haemodialysis</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0120"><ce:list-item id="u0510"><ce:label>•</ce:label><ce:para id="p0640">Ethylene glycol</ce:para></ce:list-item><ce:list-item id="u0515"><ce:label>•</ce:label><ce:para id="p0645">Isopropanol</ce:para></ce:list-item><ce:list-item id="u0520"><ce:label>•</ce:label><ce:para id="p0650">Methanol</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0125"><ce:list-item id="u0525"><ce:label>•</ce:label><ce:para id="p0655">Salicylates</ce:para></ce:list-item><ce:list-item id="u0530"><ce:label>•</ce:label><ce:para id="p0660">Sodium valproate</ce:para></ce:list-item><ce:list-item id="u0535"><ce:label>•</ce:label><ce:para id="p0665">Lithium</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Haemoperfusion</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0130"><ce:list-item id="u0540"><ce:label>•</ce:label><ce:para id="p0670">Theophylline</ce:para></ce:list-item><ce:list-item id="u0545"><ce:label>•</ce:label><ce:para id="p0675">Phenytoin</ce:para></ce:list-item><ce:list-item id="u0550"><ce:label>•</ce:label><ce:para id="p0680">Carbamazepine</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0135"><ce:list-item id="u0555"><ce:label>•</ce:label><ce:para id="p0685">Phenobarbital</ce:para></ce:list-item><ce:list-item id="u0560"><ce:label>•</ce:label><ce:para id="p0690">Amobarbital</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0050" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0065" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0130" role="short">Image 8</ce:alt-text></ce:inline-figure>7.8</ce:label><ce:alt-text id="atte0135" role="short">7.8</ce:alt-text><ce:textbox-head><ce:title id="tit0055">Complications of poisoning and their management</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0735"><ce:display><ce:table frame="topbot" id="t0030"><ce:alt-text id="atte0140" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Complication</entry><entry align="left">Examples of causative agents</entry><entry align="left">Management</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Coma</ce:bold></entry><entry align="left">Sedative agents</entry><entry align="left"><ce:list id="ulist0140"><ce:list-item id="u0565"><ce:para id="p0740">Appropriate airway protection and ventilatory support</ce:para></ce:list-item><ce:list-item id="u0570"><ce:para id="p0745">Oxygen saturation and blood gas monitoring</ce:para></ce:list-item><ce:list-item id="u0575"><ce:para id="p0750">Pressure area and bladder care</ce:para></ce:list-item><ce:list-item id="u0580"><ce:para id="p0755">Identification and treatment of aspiration pneumonia</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Seizures</ce:bold></entry><entry align="left"><ce:list id="ulist0145"><ce:list-item id="u0585"><ce:para id="p0760">NSAIDs</ce:para></ce:list-item><ce:list-item id="u0590"><ce:para id="p0765">Anticonvulsants</ce:para></ce:list-item><ce:list-item id="u0595"><ce:para id="p0770">TCAs</ce:para></ce:list-item><ce:list-item id="u0600"><ce:para id="p0775">Theophylline</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0150"><ce:list-item id="u0605"><ce:para id="p0780">Appropriate airway and ventilatory support</ce:para></ce:list-item><ce:list-item id="u0610"><ce:para id="p0785">IV benzodiazepine (e.g. diazepam 10–20 mg, lorazepam 2–4 mg)</ce:para></ce:list-item><ce:list-item id="u0615"><ce:para id="p0790">Correction of hypoxia, acid–base and metabolic abnormalities</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Acute dystonias</ce:bold></entry><entry align="left"><ce:list id="ulist0155"><ce:list-item id="u0620"><ce:para id="p0795">Typical antipsychotics</ce:para></ce:list-item><ce:list-item id="u0625"><ce:para id="p0800">Metoclopramide</ce:para></ce:list-item></ce:list></entry><entry align="left">Procyclidine, benzatropine or diazepam</entry></row><row rowsep="0"><entry align="left"><ce:bold>Hypotension</ce:bold></entry><entry align="left"/><entry align="left"/></row><row rowsep="0"><entry align="left">Due to vasodilatation</entry><entry align="left"><ce:list id="ulist0160"><ce:list-item id="u0630"><ce:para id="p0805">Vasodilator antihypertensives</ce:para></ce:list-item><ce:list-item id="u0635"><ce:para id="p0810">Anticholinergic agents</ce:para></ce:list-item><ce:list-item id="u0640"><ce:para id="p0815">TCAs</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0165"><ce:list-item id="u0645"><ce:para id="p0820">IV fluids</ce:para></ce:list-item><ce:list-item id="u0650"><ce:para id="p0825">Vasopressors (rarely indicated; <ce:intra-ref id="ii0090" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0765">p. 206</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Due to myocardial suppression</entry><entry align="left"><ce:list id="ulist0170"><ce:list-item id="u0655"><ce:para id="p0830">β-blockers</ce:para></ce:list-item><ce:list-item id="u0660"><ce:para id="p0835">Calcium channel blockers</ce:para></ce:list-item><ce:list-item id="u0665"><ce:para id="p0840">TCAs</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0175"><ce:list-item id="u0670"><ce:para id="p0845">Optimisation of volume status</ce:para></ce:list-item><ce:list-item id="u0675"><ce:para id="p0850">Inotropic agents (<ce:intra-ref id="ii0095" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0765">p. 206</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Ventricular tachycardia</ce:bold></entry><entry align="left"/></row><row rowsep="0"><entry align="left">Monomorphic, associated with QRS prolongation</entry><entry align="left">Sodium channel blockers</entry><entry align="left"><ce:list id="ulist0180"><ce:list-item id="u0680"><ce:para id="p0855">Correction of electrolyte and acid–base abnormalities and hypoxia</ce:para></ce:list-item><ce:list-item id="u0685"><ce:para id="p0860">Sodium bicarbonate (e.g. 50 mL 8.4% solution, repeated if necessary)</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left">Torsades de pointes, associated with QT<ce:inf loc="post">c</ce:inf> prolongation</entry><entry align="left"><ce:list id="ulist0185"><ce:list-item id="u0690"><ce:para id="p0865">Anti-arrhythmic drugs (quinidine, amiodarone, sotalol)</ce:para></ce:list-item><ce:list-item id="u0695"><ce:para id="p0870">Antimalarials</ce:para></ce:list-item><ce:list-item id="u0700"><ce:para id="p0875">Organophosphate insecticides</ce:para></ce:list-item><ce:list-item id="u0705"><ce:para id="p0880">Antipsychotic agents</ce:para></ce:list-item><ce:list-item id="u0710"><ce:para id="p0885">Antidepressants</ce:para></ce:list-item><ce:list-item id="u0715"><ce:para id="p0890">Antibiotics (erythromycin)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0190"><ce:list-item id="u0720"><ce:para id="p0895">Correction of electrolyte and acid–base abnormalities and hypoxia</ce:para></ce:list-item><ce:list-item id="u0725"><ce:para id="p0900">Magnesium sulphate, 2 g IV over 1–2 mins, repeated if necessary</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0025">(NSAID = non-steroidal anti-inflammatory drug; TCA = tricyclic antidepressant)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0055" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0070" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0145" role="short">Image 9</ce:alt-text></ce:inline-figure>7.9</ce:label><ce:alt-text id="atte0150" role="short">7.9</ce:alt-text><ce:textbox-head><ce:title id="tit0060">Specific antidotes used to treat poisoning</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0910"><ce:display><ce:table frame="topbot" id="t0035"><ce:alt-text id="atte0155" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Mechanism of action</entry><entry align="left">Examples of antidote</entry><entry align="left">Poisoning treated</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Glutathione repleters</ce:bold></entry><entry align="left">Acetylcysteine<ce:br/>Methionine</entry><entry align="left">Paracetamol</entry></row><row><entry morerows="2" rowsep="1" align="left"><ce:bold>Receptor antagonists</ce:bold></entry><entry rowsep="0" align="left">Naloxone</entry><entry rowsep="0" align="left">Opioids</entry></row><row rowsep="0"><entry align="left">Flumazenil</entry><entry align="left">Benzodiazepines</entry></row><row rowsep="1"><entry align="left">Atropine</entry><entry align="left">Organophosphorus compounds<ce:br/>Carbamates</entry></row><row rowsep="1"><entry align="left"><ce:bold>Alcohol dehydrogenase inhibitors</ce:bold></entry><entry align="left">Fomepizole<ce:br/>Ethanol</entry><entry align="left">Ethylene glycol<ce:br/>Methanol</entry></row><row><entry morerows="2" rowsep="1" align="left"><ce:bold>Chelating agents</ce:bold></entry><entry rowsep="0" align="left">Desferrioxamine</entry><entry rowsep="0" align="left">Iron</entry></row><row rowsep="0"><entry align="left">Hydroxocobalamin<ce:br/>Dicobalt edetate</entry><entry align="left">Cyanide</entry></row><row rowsep="1"><entry align="left">DMSA<ce:br/>Sodium calcium edetate</entry><entry align="left">Lead</entry></row><row rowsep="1"><entry align="left"><ce:bold>Reducing agents</ce:bold></entry><entry align="left">Methylthioninium chloride</entry><entry align="left">Organic nitrites</entry></row><row rowsep="1"><entry align="left"><ce:bold>Cholinesterase reactivators</ce:bold></entry><entry align="left">Pralidoxime</entry><entry align="left">Organophosphorus compounds</entry></row><row><entry align="left"><ce:bold>Antibody fragments</ce:bold></entry><entry align="left">Digoxin Fab fragments</entry><entry align="left">Digoxin</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0030">(DMSA = dimercaptosuccinic acid)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0060" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0080" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0160" role="short">Image 10</ce:alt-text></ce:inline-figure>7.10</ce:label><ce:alt-text id="atte0165" role="short">7.10</ce:alt-text><ce:textbox-head><ce:title id="tit0065">Anticholinergic and serotonergic feature clusters</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0985"><ce:display><ce:table frame="topbot" id="t0040"><ce:alt-text id="atte0170" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Anticholinergic</entry><entry align="left">Serotonin syndrome</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Common causes</ce:bold></entry><entry align="left"><ce:list id="ulist0195"><ce:list-item id="u0730"><ce:para id="p0990">Benzodiazepines</ce:para></ce:list-item><ce:list-item id="u0735"><ce:para id="p0995">Antipsychotics</ce:para></ce:list-item><ce:list-item id="u0740"><ce:para id="p1000">TCAs</ce:para></ce:list-item><ce:list-item id="u0745"><ce:para id="p1005">Antihistamines</ce:para></ce:list-item><ce:list-item id="u0750"><ce:para id="p1010">Scopolamine</ce:para></ce:list-item><ce:list-item id="u0755"><ce:para id="p1015">Benzatropine</ce:para></ce:list-item><ce:list-item id="u0760"><ce:para id="p1020">Belladonna</ce:para></ce:list-item><ce:list-item id="u0765"><ce:para id="p1025">Some plants and mushrooms (see <ce:cross-ref id="crf0300" refid="b0100">Box 7.18</ce:cross-ref>)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0200"><ce:list-item id="u0770"><ce:para id="p1030">SSRIs</ce:para></ce:list-item><ce:list-item id="u0775"><ce:para id="p1035">MAOIs</ce:para></ce:list-item><ce:list-item id="u0780"><ce:para id="p1040">TCAs</ce:para></ce:list-item><ce:list-item id="u0785"><ce:para id="p1045">Amphetamines</ce:para></ce:list-item><ce:list-item id="u0790"><ce:para id="p1050">Tryptamines</ce:para></ce:list-item><ce:list-item id="u0795"><ce:para id="p1055">Buspirone</ce:para></ce:list-item><ce:list-item id="u0800"><ce:para id="p1060">Bupropion (especially in combination)</ce:para></ce:list-item></ce:list></entry></row><row rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Clinical features</ce:bold></entry></row><row rowsep="0"><entry align="left">Cardiovascular</entry><entry align="left">Tachycardia, hypertension</entry><entry align="left">Tachycardia, hyper- or hypotension</entry></row><row rowsep="0"><entry align="left">Central nervous system</entry><entry align="left">Delirium, hallucinations, sedation</entry><entry align="left">Delirium, hallucinations, sedation, coma</entry></row><row rowsep="0"><entry align="left">Muscle</entry><entry align="left">Myoclonus</entry><entry align="left">Shivering, tremor, myoclonus, raised creatine kinase</entry></row><row rowsep="0"><entry align="left">Temperature</entry><entry align="left">Fever</entry><entry align="left">Fever</entry></row><row rowsep="0"><entry align="left">Eyes</entry><entry align="left">Diplopia, mydriasis</entry><entry align="left">Normal pupil size</entry></row><row rowsep="0"><entry align="left">Abdomen</entry><entry align="left">Ileus, palpable bladder</entry><entry align="left">Diarrhoea, vomiting</entry></row><row rowsep="0"><entry align="left">Mouth</entry><entry align="left">Dry</entry><entry align="left"/></row><row rowsep="1"><entry align="left">Skin</entry><entry align="left">Flushing, hot, dry</entry><entry align="left">Flushing, sweating</entry></row><row><entry align="left"><ce:bold>Complications</ce:bold></entry><entry align="left">Seizures</entry><entry align="left"><ce:list id="ulist0205"><ce:list-item id="u0805"><ce:para id="p1065">Seizures</ce:para></ce:list-item><ce:list-item id="u0810"><ce:para id="p1070">Rhabdomyolysis</ce:para></ce:list-item><ce:list-item id="u0815"><ce:para id="p1075">Renal failure</ce:para></ce:list-item><ce:list-item id="u0820"><ce:para id="p1080">Metabolic acidosis</ce:para></ce:list-item><ce:list-item id="u0825"><ce:para id="p1085">Coagulopathies</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0040">(MAOI = monoamine oxidase inhibitor; SSRI = selective serotonin re-uptake inhibitor; TCA = tricyclic antidepressant)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0065" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0090" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0175" role="short">Image 11</ce:alt-text></ce:inline-figure>7.11</ce:label><ce:alt-text id="atte0180" role="short">7.11</ce:alt-text><ce:textbox-head><ce:title id="tit0070">Clinical features and specific management of drugs less commonly involved in poisoning</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1255"><ce:display><ce:table frame="topbot" id="t0045"><ce:alt-text id="atte0185" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Substance</entry><entry align="left">Clinical features</entry><entry align="left">Management</entry></row></thead><tbody><row rowsep="0"><entry align="left"><ce:bold>Anticonvulsants</ce:bold></entry><entry namest="col2" nameend="col3" align="left"/></row><row rowsep="0"><entry align="left">Carbamazepine, phenytoin</entry><entry align="left"><ce:list id="ulist0210"><ce:list-item id="u0830"><ce:para id="p1260">Cerebellar signs</ce:para></ce:list-item><ce:list-item id="u0835"><ce:para id="p1265">Convulsions</ce:para></ce:list-item><ce:list-item id="u0840"><ce:para id="p1270">Cardiac arrhythmias</ce:para></ce:list-item><ce:list-item id="u0845"><ce:para id="p1275">Coma</ce:para></ce:list-item></ce:list></entry><entry align="left">Multiple-dose activated charcoal (carbamazepine)</entry></row><row rowsep="1"><entry align="left">Sodium valproate</entry><entry align="left"><ce:list id="ulist0215"><ce:list-item id="u0850"><ce:para id="p1280">Coma</ce:para></ce:list-item><ce:list-item id="u0855"><ce:para id="p1285">Metabolic acidosis</ce:para></ce:list-item></ce:list></entry><entry align="left">Haemodialysis for severe poisoning</entry></row><row rowsep="1"><entry align="left"><ce:bold>Isoniazid</ce:bold></entry><entry align="left"><ce:list id="ulist0220"><ce:list-item id="u0860"><ce:para id="p1290">Peripheral neuropathy</ce:para></ce:list-item><ce:list-item id="u0865"><ce:para id="p1295">Convulsions</ce:para></ce:list-item></ce:list></entry><entry align="left">Activated charcoal<ce:br/>IV pyridoxine</entry></row><row rowsep="1"><entry align="left"><ce:bold>Theophylline</ce:bold></entry><entry align="left"><ce:list id="ulist0225"><ce:list-item id="u0870"><ce:para id="p1300">Cardiac arrhythmias</ce:para></ce:list-item><ce:list-item id="u0875"><ce:para id="p1305">Convulsions</ce:para></ce:list-item><ce:list-item id="u0880"><ce:para id="p1310">Coma</ce:para></ce:list-item></ce:list></entry><entry align="left">Multiple-dose activated charcoal</entry></row><row rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Antimalarial drugs</ce:bold></entry></row><row rowsep="0"><entry align="left">Chloroquine</entry><entry align="left"><ce:list id="ulist0230"><ce:list-item id="u0885"><ce:para id="p1315">Acidosis and hypokalaemia</ce:para></ce:list-item><ce:list-item id="u0890"><ce:para id="p1320">Visual loss</ce:para></ce:list-item><ce:list-item id="u0895"><ce:para id="p1325">Convulsions, coma</ce:para></ce:list-item><ce:list-item id="u0900"><ce:para id="p1330">ECG changes and arrhythmias</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0235"><ce:list-item id="u0905"><ce:para id="p1335">Correction of pH (but not potassium)</ce:para></ce:list-item><ce:list-item id="u0910"><ce:para id="p1340">Monitoring and treatment of cardiac rhythm</ce:para></ce:list-item><ce:list-item id="u0915"><ce:para id="p1345">High-dose diazepam with mechanical ventilation</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left">Quinine</entry><entry align="left"><ce:list id="ulist0240"><ce:list-item id="u0920"><ce:para id="p1350">Tremor, tinnitus, deafness, ataxia, convulsions, coma</ce:para></ce:list-item><ce:list-item id="u0925"><ce:para id="p1355">Haemolysis</ce:para></ce:list-item><ce:list-item id="u0930"><ce:para id="p1360">ECG changes and arrhythmias</ce:para></ce:list-item><ce:list-item id="u0935"><ce:para id="p1365">Retinal toxicity</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0245"><ce:list-item id="u0940"><ce:para id="p1370">Correction of pH (but not potassium)</ce:para></ce:list-item><ce:list-item id="u0945"><ce:para id="p1375">Monitoring and treatment of cardiac rhythm</ce:para></ce:list-item><ce:list-item id="u0950"><ce:para id="p1380">Multiple-dose activated charcoal</ce:para></ce:list-item><ce:list-item id="u0955"><ce:para id="p1385">No effective treatment for visual loss</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0070" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0095" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0190" role="short">Image 12</ce:alt-text></ce:inline-figure>7.12</ce:label><ce:alt-text id="atte0195" role="short">7.12</ce:alt-text><ce:textbox-head><ce:title id="tit0075">Stimulant, sedative and opioid feature clusters</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1400"><ce:display><ce:table frame="topbot" id="t0050"><ce:alt-text id="atte0200" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Stimulant</entry><entry align="left">Sedative hypnotic</entry><entry align="left">Opioid</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Common causes</ce:bold></entry><entry align="left"><ce:list id="ulist0250"><ce:list-item id="u0960"><ce:para id="p1405">Amphetamines</ce:para></ce:list-item><ce:list-item id="u0965"><ce:para id="p1410">MDMA (‘ecstasy’)</ce:para></ce:list-item><ce:list-item id="u0970"><ce:para id="p1415">Ephedrine</ce:para></ce:list-item><ce:list-item id="u0975"><ce:para id="p1420">Pseudoephedrine</ce:para></ce:list-item><ce:list-item id="u0980"><ce:para id="p1425">Cocaine</ce:para></ce:list-item><ce:list-item id="u0985"><ce:para id="p1430">Cannabis</ce:para></ce:list-item><ce:list-item id="u0990"><ce:para id="p1435">Phencyclidine</ce:para></ce:list-item><ce:list-item id="u0995"><ce:para id="p1440">Cathinones (e.g. mephedrone)</ce:para></ce:list-item><ce:list-item id="u1000"><ce:para id="p1445">Benzylpiperazine</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0255"><ce:list-item id="u1005"><ce:para id="p1450">Benzodiazepines</ce:para></ce:list-item><ce:list-item id="u1010"><ce:para id="p1455">Barbiturates</ce:para></ce:list-item><ce:list-item id="u1015"><ce:para id="p1460">Ethanol</ce:para></ce:list-item><ce:list-item id="u1020"><ce:para id="p1465">GHB</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0260"><ce:list-item id="u1025"><ce:para id="p1470">Heroin</ce:para></ce:list-item><ce:list-item id="u1030"><ce:para id="p1475">Morphine</ce:para></ce:list-item><ce:list-item id="u1035"><ce:para id="p1480">Methadone</ce:para></ce:list-item><ce:list-item id="o9000"><ce:para id="p9000">Fentanyl and derivatives</ce:para></ce:list-item><ce:list-item id="u1040"><ce:para id="p1485">Oxycodone</ce:para></ce:list-item><ce:list-item id="u1045"><ce:para id="p1490">Dihydrocodeine</ce:para></ce:list-item><ce:list-item id="u1050"><ce:para id="p1495">Codeine</ce:para></ce:list-item><ce:list-item id="u1055"><ce:para id="p1500">Pethidine</ce:para></ce:list-item><ce:list-item id="u1065"><ce:para id="p1510">Buprenorphine</ce:para></ce:list-item><ce:list-item id="u1070"><ce:para id="p1515">Dextropropoxyphene</ce:para></ce:list-item><ce:list-item id="u1075"><ce:para id="p1520">Tramadol</ce:para></ce:list-item></ce:list></entry></row><row rowsep="0"><entry namest="col1" nameend="col4" align="left"><ce:bold>Clinical features</ce:bold></entry></row><row rowsep="0"><entry align="left">Respiratory</entry><entry align="left">Tachypnoea</entry><entry align="left">Reduced respiratory rate and ventilation<ce:cross-ref id="crf0355" refid="tn0030"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry><entry align="left">Reduced respiratory rate and ventilation</entry></row><row rowsep="0"><entry align="left">Cardiovascular</entry><entry align="left">Tachycardia, hypertension</entry><entry align="left">Hypotension<ce:cross-ref id="crf0360" refid="tn0030"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry><entry align="left">Hypotension, relative bradycardia</entry></row><row rowsep="0"><entry morerows="1" align="left">Central nervous system</entry><entry align="left">Restlessness, anxiety, anorexia, insomnia</entry><entry align="left">Delirium, hallucinations, slurred speech</entry><entry align="left">Delirium, hallucinations, slurred speech</entry></row><row rowsep="0"><entry align="left">Hallucinations</entry><entry align="left">Sedation, coma<ce:cross-ref id="crf0365" refid="tn0030"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry><entry align="left">Sedation, coma<ce:cross-ref id="crf0370" refid="tn0035"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry></row><row rowsep="0"><entry align="left">Muscle</entry><entry align="left">Tremor</entry><entry align="left">Ataxia, reduced muscle tone</entry><entry align="left">Ataxia, reduced muscle tone</entry></row><row rowsep="0"><entry align="left">Temperature</entry><entry align="left">Fever</entry><entry align="left">Hypothermia</entry><entry align="left">Hypothermia</entry></row><row rowsep="0"><entry align="left">Eyes</entry><entry align="left">Mydriasis</entry><entry align="left">Diplopia, strabismus, nystagmus<ce:br/>Normal pupil size</entry><entry align="left">Miosis</entry></row><row rowsep="0"><entry align="left">Abdomen</entry><entry align="left">Abdominal pain, diarrhoea</entry><entry align="left">–</entry><entry align="left">Ileus</entry></row><row rowsep="0"><entry align="left">Mouth</entry><entry align="left">Dry</entry><entry align="left">–</entry><entry align="left">–</entry></row><row rowsep="1"><entry align="left">Skin</entry><entry align="left">Piloerection</entry><entry align="left">Blisters, pressure sores</entry><entry align="left">Needle tracks<ce:cross-ref id="crf0375" refid="tn0035"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry></row><row><entry align="left"><ce:bold>Complications</ce:bold></entry><entry align="left"><ce:list id="ulist0265"><ce:list-item id="u1080"><ce:para id="p1525">Seizures</ce:para></ce:list-item><ce:list-item id="u1085"><ce:para id="p1530">Myocardial infarction</ce:para></ce:list-item><ce:list-item id="u1090"><ce:para id="p1535">Dysrhythmias</ce:para></ce:list-item><ce:list-item id="u1095"><ce:para id="p1540">Rhabdomyolysis</ce:para></ce:list-item><ce:list-item id="u1100"><ce:para id="p1545">Renal failure</ce:para></ce:list-item><ce:list-item id="u1105"><ce:para id="p1550">Intracerebral haemorrhage or infarction</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0270"><ce:list-item id="u1110"><ce:para id="p1555">Respiratory failure<ce:cross-ref id="crf0380" refid="tn0030"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u1115"><ce:para id="p1560">Aspiration</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0275"><ce:list-item id="u1120"><ce:para id="p1565">Respiratory failure<ce:cross-ref id="crf0385" refid="tn0035"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u1125"><ce:para id="p1570">Non-cardiogenic pulmonary oedema</ce:para></ce:list-item><ce:list-item id="u1130"><ce:para id="p1575">Aspiration</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0055">(GHB = gamma hydroxybutyrate; MDMA = 3,4-methylene-dioxymethamphetamine)</ce:simple-para></ce:legend><ce:table-footnote id="tn0030"><ce:label>1</ce:label><ce:note-para id="np0030">Especially barbiturates.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0035"><ce:label>2</ce:label><ce:note-para id="np0035">IV use.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0075" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0105" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0205" role="short">Image 13</ce:alt-text></ce:inline-figure>7.13</ce:label><ce:alt-text id="atte0210" role="short">7.13</ce:alt-text><ce:textbox-head><ce:title id="tit0080">Organophosphorus compounds</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1755"><ce:display><ce:table frame="topbot" id="t0055"><ce:alt-text id="atte0215" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Nerve agents</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0280"><ce:list-item id="u1135"><ce:label>•</ce:label><ce:para id="p1760">G agents: sarin, tabun, soman</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0285"><ce:list-item id="u1140"><ce:label>•</ce:label><ce:para id="p1765">V agents: VX,VE</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Insecticides</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:bold>Dimethyl compounds</ce:bold></entry><entry align="left"><ce:bold>Diethyl compounds</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0290"><ce:list-item id="u1145"><ce:label>•</ce:label><ce:para id="p1770">Dichlorvos</ce:para></ce:list-item><ce:list-item id="u1150"><ce:label>•</ce:label><ce:para id="p1775">Fenthion</ce:para></ce:list-item><ce:list-item id="u1155"><ce:label>•</ce:label><ce:para id="p1780">Malathion</ce:para></ce:list-item><ce:list-item id="u1160"><ce:label>•</ce:label><ce:para id="p1785">Methamidophos</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0295"><ce:list-item id="u1165"><ce:label>•</ce:label><ce:para id="p1790">Chlorpyrifos</ce:para></ce:list-item><ce:list-item id="u1170"><ce:label>•</ce:label><ce:para id="p1795">Diazinon</ce:para></ce:list-item><ce:list-item id="u1175"><ce:label>•</ce:label><ce:para id="p1800">Parathion-ethyl</ce:para></ce:list-item><ce:list-item id="u1180"><ce:label>•</ce:label><ce:para id="p1805">Quinalphos</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0080" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0115" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0220" role="short">Image 14</ce:alt-text></ce:inline-figure>7.14</ce:label><ce:alt-text id="atte0225" role="short">7.14</ce:alt-text><ce:textbox-head><ce:title id="tit0085">Cholinergic features in poisoning<ce:cross-ref id="crf0475" refid="tn0040">*</ce:cross-ref></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1835"><ce:display><ce:table frame="topbot" id="t0060"><ce:alt-text id="atte0230" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Muscarinic</entry><entry align="left">Nicotinic</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Respiratory</ce:bold></entry><entry align="left">Bronchorrhoea, bronchoconstriction</entry><entry align="left">Reduced ventilation</entry></row><row rowsep="1"><entry align="left"><ce:bold>Circulation</ce:bold></entry><entry align="left">Bradycardia, hypotension</entry><entry align="left">Tachycardia, hypertension</entry></row><row rowsep="1"><entry align="left"><ce:bold>Higher mental function</ce:bold></entry><entry namest="col2" nameend="col3" align="left">Anxiety, delirium, psychosis</entry></row><row rowsep="1"><entry align="left"><ce:bold>Muscle</ce:bold></entry><entry align="left">–</entry><entry align="left">Fasciculation, paralysis</entry></row><row rowsep="1"><entry align="left"><ce:bold>Temperature</ce:bold></entry><entry align="left">Fever</entry><entry align="left">–</entry></row><row rowsep="1"><entry align="left"><ce:bold>Eyes</ce:bold></entry><entry align="left">Diplopia, miosis, lacrimation</entry><entry align="left">Mydriasis</entry></row><row rowsep="1"><entry align="left"><ce:bold>Abdomen</ce:bold></entry><entry align="left">Vomiting, profuse diarrhoea</entry><entry align="left">–</entry></row><row rowsep="1"><entry align="left"><ce:bold>Mouth</ce:bold></entry><entry align="left">Salivation</entry><entry align="left">–</entry></row><row rowsep="1"><entry align="left"><ce:bold>Skin</ce:bold></entry><entry align="left">Sweating</entry><entry align="left">–</entry></row><row><entry align="left"><ce:bold>Complications</ce:bold></entry><entry namest="col2" nameend="col3" align="center">Coma, seizures, respiratory depression</entry></row></tbody></tgroup><ce:table-footnote id="tn0040"><ce:label>*</ce:label><ce:note-para id="np0040">Both muscarinic and nicotinic features occur in OP poisoning. Nicotinic features occur in nicotine poisoning and black widow spider bites. Cholinergic features are sometimes seen with some mushrooms.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0085" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0125" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0235" role="short">Image 15</ce:alt-text></ce:inline-figure>7.15</ce:label><ce:alt-text id="atte0240" role="short">7.15</ce:alt-text><ce:textbox-head><ce:title id="tit0090">Clinical features and specific management of chemicals less commonly involved in poisoning</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1980"><ce:display><ce:table frame="topbot" id="t0065"><ce:alt-text id="atte0245" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Substance</entry><entry align="left">Clinical features</entry><entry align="left">Management</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Lead</ce:bold></entry></row><row rowsep="1"><entry align="left">e.g. Chronic occupational exposure, leaded paint, water contaminated by lead pipes, use of kohl cosmetics</entry><entry align="left"><ce:list id="ulist0300"><ce:list-item id="u1185"><ce:para id="p1985">Abdominal pain</ce:para></ce:list-item><ce:list-item id="u1190"><ce:para id="p1990">Microcytic anaemia with basophilic stippling</ce:para></ce:list-item><ce:list-item id="u1195"><ce:para id="p1995">Headache and encephalopathy</ce:para></ce:list-item><ce:list-item id="u1200"><ce:para id="p2000">Motor neuropathy</ce:para></ce:list-item><ce:list-item id="u1205"><ce:para id="p2005">Nephrotoxicity</ce:para></ce:list-item><ce:list-item id="u1210"><ce:para id="p2010">Hypertension</ce:para></ce:list-item><ce:list-item id="u1215"><ce:para id="p2015">Hypocalcaemia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0305"><ce:list-item id="u1220"><ce:para id="p2020">Prevention of further exposure</ce:para></ce:list-item><ce:list-item id="u1225"><ce:para id="p2025">Measurement of blood lead concentration, full blood count and blood film, urea and electrolytes, liver function tests and calcium</ce:para></ce:list-item><ce:list-item id="u1230"><ce:para id="p2030">Abdominal X-ray in children to detect pica</ce:para></ce:list-item><ce:list-item id="u1235"><ce:para id="p2035">Bone X-ray for ‘lead lines’</ce:para></ce:list-item><ce:list-item id="u1240"><ce:para id="p2040">Chelation therapy with DMSA or sodium calcium edetate</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Petroleum distillates</ce:bold></entry></row><row rowsep="1"><entry align="left">e.g. White spirit, kerosene</entry><entry align="left"><ce:list id="ulist0310"><ce:list-item id="u1245"><ce:para id="p2045">Vomiting</ce:para></ce:list-item><ce:list-item id="u1250"><ce:para id="p2050">Aspiration pneumonitis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0315"><ce:list-item id="u1255"><ce:para id="p2055">Gastric lavage contraindicated</ce:para></ce:list-item><ce:list-item id="u1260"><ce:para id="p2060">Activated charcoal ineffective</ce:para></ce:list-item><ce:list-item id="u1265"><ce:para id="p2065">Oxygen and nebulised bronchodilators</ce:para></ce:list-item><ce:list-item id="u1270"><ce:para id="p2070">Chest X-ray to assess pulmonary effects</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Organochlorines</ce:bold></entry></row><row rowsep="1"><entry align="left">e.g. DDT, lindane, dieldrin, endosulfan</entry><entry align="left"><ce:list id="ulist0320"><ce:list-item id="u1275"><ce:para id="p2075">Nausea, vomiting</ce:para></ce:list-item><ce:list-item id="u1280"><ce:para id="p2080">Agitation</ce:para></ce:list-item><ce:list-item id="u1285"><ce:para id="p2085">Fasciculation</ce:para></ce:list-item><ce:list-item id="u1290"><ce:para id="p2090">Paraesthesiae (face, extremities)</ce:para></ce:list-item><ce:list-item id="u1295"><ce:para id="p2095">Convulsions</ce:para></ce:list-item><ce:list-item id="u1300"><ce:para id="p2100">Coma</ce:para></ce:list-item><ce:list-item id="u1305"><ce:para id="p2105">Respiratory depression</ce:para></ce:list-item><ce:list-item id="u1310"><ce:para id="p2110">Cardiac arrhythmias</ce:para></ce:list-item><ce:list-item id="u1315"><ce:para id="p2115">Hyperthermia</ce:para></ce:list-item><ce:list-item id="u1320"><ce:para id="p2120">Rhabdomyolysis</ce:para></ce:list-item><ce:list-item id="u1325"><ce:para id="p2125">Pulmonary oedema</ce:para></ce:list-item><ce:list-item id="u1330"><ce:para id="p2130">Disseminated intravascular coagulation</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0325"><ce:list-item id="u1335"><ce:para id="p2135">Activated charcoal (with nasogastric aspiration for liquid preparations) within 1 hr of ingestion</ce:para></ce:list-item><ce:list-item id="u1340"><ce:para id="p2140">Cardiac monitoring</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Pyrethroid insecticides</ce:bold></entry></row><row rowsep="1"><entry align="left">e.g. Cypermethrin, permethrin, imiprothrin</entry><entry align="left"><ce:list id="ulist0330"><ce:list-item id="u1345"><ce:para id="p2145">Skin contact: dermatitis, skin paraesthesiae</ce:para></ce:list-item><ce:list-item id="u1350"><ce:para id="p2150">Eye contact: lacrimation, photophobia and oedema of the eyelids</ce:para></ce:list-item><ce:list-item id="u1355"><ce:para id="p2155">Inhalation: dyspnoea, nausea, headaches</ce:para></ce:list-item><ce:list-item id="u1360"><ce:para id="p2160">Ingestion: epigastric pain, nausea, vomiting, headache, coma, convulsions, pulmonary oedema</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0335"><ce:list-item id="u1365"><ce:para id="p2165">Symptomatic and supportive care</ce:para></ce:list-item><ce:list-item id="u1370"><ce:para id="p2170">Washing contaminated skin makes irritation worse</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Anticoagulant rodenticides</ce:bold></entry></row><row><entry align="left">e.g. Brodifacoum, bromadialone and warfarin</entry><entry align="left">Abnormal bleeding (prolonged)</entry><entry align="left"><ce:list id="ulist0340"><ce:list-item id="u1375"><ce:para id="p2175">Monitor INR/prothrombin time</ce:para></ce:list-item><ce:list-item id="u1380"><ce:para id="p2180">Vitamin K<ce:inf loc="post">1</ce:inf> by slow IV injection if there is coagulopathy</ce:para></ce:list-item><ce:list-item id="u1385"><ce:para id="p2185">Fresh frozen plasma or specific clotting factors for bleeding</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0075">(DMSA = dimercaptosuccinic acid)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0090" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0130" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0250" role="short">Image 16</ce:alt-text></ce:inline-figure>7.16</ce:label><ce:alt-text id="atte0255" role="short">7.16</ce:alt-text><ce:textbox-head><ce:title id="tit0095">Chemical warfare agents</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2195"><ce:display><ce:table frame="topbot" id="t0070"><ce:alt-text id="atte0260" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Examples</entry><entry align="left">Clinical effects</entry><entry align="left">Antidotes<ce:cross-ref id="crf0515" refid="tn0045">*</ce:cross-ref></entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Nerve agents</ce:bold></entry></row><row rowsep="1"><entry align="left">Tabun<ce:br/>Sarin<ce:br/>Soman<ce:br/>VX</entry><entry align="left">See <ce:cross-ref id="crf9010" refid="p1740">page 145</ce:cross-ref> and<ce:cross-ref id="crf0520" refid="b0075">Box 7.13</ce:cross-ref></entry><entry align="left">Atropine<ce:br/>Oximes<ce:br/>(<ce:cross-ref id="crf9015" refid="p1740">p. 145</ce:cross-ref>)</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Blistering agents</ce:bold></entry></row><row rowsep="1"><entry align="left">Nitrogen/sulphur Mustard<ce:br/>Lewisite</entry><entry align="left"><ce:list id="ulist0345"><ce:list-item id="u1390"><ce:para id="p2200">Eyes: watering, blepharospasm, corneal ulceration</ce:para></ce:list-item><ce:list-item id="u1395"><ce:para id="p2205">Skin: erythema, blistering</ce:para></ce:list-item><ce:list-item id="u1400"><ce:para id="p2210">Respiratory: cough, hoarseness, dyspnoea, pneumonitis</ce:para></ce:list-item></ce:list></entry><entry align="left">None</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Choking agents</ce:bold></entry></row><row rowsep="1"><entry align="left">Chlorine<ce:br/>Phosgene</entry><entry align="left"><ce:list id="ulist0350"><ce:list-item id="u1405"><ce:para id="p2215">Eyes: watering, blepharospasm, corneal ulceration</ce:para></ce:list-item><ce:list-item id="u1410"><ce:para id="p2220">Respiratory: cough, hoarseness, dyspnoea, pneumonitis</ce:para></ce:list-item></ce:list></entry><entry align="left">None</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Blood agents</ce:bold></entry></row><row><entry align="left">Cyanide</entry><entry align="left"><ce:list id="ulist0355"><ce:list-item id="u1415"><ce:para id="p2225">Cardiovascular: dizziness, shock</ce:para></ce:list-item><ce:list-item id="u1420"><ce:para id="p2230">Respiratory: dyspnoea, cyanosis</ce:para></ce:list-item><ce:list-item id="u1425"><ce:para id="p2235">CNS: anxiety, headache, delirium, convulsions, coma, fixed dilated pupils</ce:para></ce:list-item><ce:list-item id="u1430"><ce:para id="p2240">Other: vomiting, lactic acidosis</ce:para></ce:list-item></ce:list></entry><entry align="left">Dicobalt edetate Hydroxocobalamin</entry></row></tbody></tgroup><ce:table-footnote id="tn0045"><ce:label>*</ce:label><ce:note-para id="np0045">Appropriate resuscitation, decontamination and supportive care are essential after exposure to all chemical warfare agents. Use appropriate personal protective equipment.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0095" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0135" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0265" role="short">Image 17</ce:alt-text></ce:inline-figure>7.17</ce:label><ce:alt-text id="atte0270" role="short">7.17</ce:alt-text><ce:textbox-head><ce:title id="tit0100">Clinical features of chronic arsenic poisoning</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0505"><ce:section-title id="st0480">Gastrointestinal tract</ce:section-title><ce:para id="p2255"><ce:list id="ulist0360"><ce:list-item id="u1435"><ce:label>•</ce:label><ce:para id="p2260">Anorexia, vomiting, weight loss, diarrhoea, increased salivation, metallic taste</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0510"><ce:section-title id="st0485">Neurological</ce:section-title><ce:para id="p2265"><ce:list id="ulist0365"><ce:list-item id="u1440"><ce:label>•</ce:label><ce:para id="p2270">Peripheral neuropathy (sensory and motor) with muscle wasting and fasciculation, ataxia</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0515"><ce:section-title id="st0490">Skin</ce:section-title><ce:para id="p2275"><ce:list id="ulist0370"><ce:list-item id="u1445"><ce:label>•</ce:label><ce:para id="p2280">Hyperpigmentation, palmar and plantar keratosis, alopecia, multiple epitheliomas, Mee's lines (transverse white lines on fingernails)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0520"><ce:section-title id="st0495">Eyes</ce:section-title><ce:para id="p2285"><ce:list id="ulist0375"><ce:list-item id="u1450"><ce:label>•</ce:label><ce:para id="p2290">Conjunctivitis, corneal necrosis and ulceration</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0525"><ce:section-title id="st0500">Bone marrow</ce:section-title><ce:para id="p2295"><ce:list id="ulist0380"><ce:list-item id="u1455"><ce:label>•</ce:label><ce:para id="p2300">Aplastic anaemia</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0530"><ce:section-title id="st0505">Other</ce:section-title><ce:para id="p2305"><ce:list id="ulist0385"><ce:list-item id="u1460"><ce:label>•</ce:label><ce:para id="p2310">Low-grade fever, vasospasm and gangrene, jaundice, hepatomegaly, splenomegaly</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0535"><ce:section-title id="st0510">Increased risk of malignancy</ce:section-title><ce:para id="p2315"><ce:list id="ulist0390"><ce:list-item id="u1465"><ce:label>•</ce:label><ce:para id="p2320">Lung, liver, bladder, kidney, larynx and lymphoid system</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0100" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0140" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0275" role="short">Image 18</ce:alt-text></ce:inline-figure>7.18</ce:label><ce:alt-text id="atte0280" role="short">7.18</ce:alt-text><ce:textbox-head><ce:title id="tit0105">Some poisonous plants and fungi, with their clinical effects</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2355"><ce:display><ce:table frame="topbot" id="t9000"><ce:alt-text id="atte0285" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Species (common name)</entry><entry align="left">Toxins</entry><entry align="left">Important features of toxicity</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Plants</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:italic>Abrus precatorius</ce:italic> (jequirity bean)</entry><entry align="left">Abrin</entry><entry morerows="1" align="left">Gastrointestinal effects, drowsiness, delirium, convulsions, multi-organ failure</entry></row><row rowsep="0"><entry align="left"><ce:italic>Ricinus communis</ce:italic> (castor oil plant)</entry><entry align="left">Ricin</entry></row><row rowsep="0"><entry align="left"><ce:italic>Aconitum napellus</ce:italic> (aconite, wolf's bane, monkshood)<ce:br/><ce:italic>Aconitum ferox</ce:italic> (Indian aconite, bikh)</entry><entry align="left">Aconite</entry><entry align="left">Gastrointestinal effects, paraesthesiae, convulsions, ventricular tachycardia</entry></row><row rowsep="0"><entry align="left"><ce:italic>Atropa belladonna</ce:italic> (deadly nightshade)<ce:br/><ce:italic>Datura stramonium</ce:italic> (Jimson weed, thorn apple)<ce:br/><ce:italic>Brugmansia</ce:italic> spp. (angel's trumpet)</entry><entry align="left">Atropine, scopolamine, hyocyamine</entry><entry align="left">Anticholinergic toxidrome (see <ce:cross-ref id="crf9005" refid="b0060">Box 7.10</ce:cross-ref>)</entry></row><row rowsep="0"><entry align="left"><ce:italic>Colchicum autumnale</ce:italic> (autumn crocus)</entry><entry align="left">Colchicine</entry><entry align="left">Gastrointestinal effects, hypotension, cardiogenic shock</entry></row><row rowsep="0"><entry align="left"><ce:italic>Conium maculatum</ce:italic> (hemlock)</entry><entry align="left">Toxic nicotinic alkaloids</entry><entry align="left">Hypersalivation, gastrointestinal effects, followed by muscular paralysis</entry></row><row rowsep="0"><entry align="left"><ce:italic>Digitalis purpurea</ce:italic> (foxglove)<ce:br/><ce:italic>Nerium oleander</ce:italic> (pink oleander)<ce:br/><ce:italic>Thevetia peruviana</ce:italic> (yellow oleander)</entry><entry align="left">Cardiac glycosides</entry><entry align="left">Cardiac glycoside toxicity (<ce:cross-ref id="crf9020" refid="s0190">p. 140</ce:cross-ref>)</entry></row><row rowsep="0"><entry align="left"><ce:italic>Laburnum anagyroides</ce:italic> (laburnum)</entry><entry align="left">Cytosine</entry><entry align="left">Gastrointestinal effects; convulsions in severe cases</entry></row><row rowsep="1"><entry align="left"><ce:italic>Taxus baccata</ce:italic> (yew)</entry><entry align="left">Taxane alkaloids</entry><entry align="left">Hypotension, bradycardia, respiratory depression, convulsions, coma, arrhythmias</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Fungi</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:italic>Amanita phalloides</ce:italic><ce:br/>(death cap mushroom)</entry><entry align="left">Amatoxins</entry><entry align="left">Gastrointestinal effects, progressing to liver failure</entry></row><row rowsep="0"><entry align="left"><ce:italic>Cortinarius</ce:italic> spp.</entry><entry align="left">Orellanine</entry><entry align="left">Gastrointestinal effects, fever, progressing to renal failure</entry></row><row><entry align="left"><ce:italic>Psilocybe semilanceata</ce:italic><ce:br/>(‘magic mushrooms’)</entry><entry align="left">Psilocybin, psilocin</entry><entry align="left">Hallucinations</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:floats><ce:label>7</ce:label><ce:title id="tit0010">Poisoning</ce:title><ce:author-group id="aug0010"><ce:author author-id="B978070207028000007X-d5fad86e348c745c2234e33e0e705159" id="au0010"><ce:given-name>SHL</ce:given-name><ce:surname>Thomas</ce:surname></ce:author></ce:author-group><outline id="out0010"><ce:list id="ulist0010"><ce:list-item id="u0010"><ce:para id="p0010"><ce:bold>Comprehensive evaluation of the poisoned patient</ce:bold> <ce:cross-ref id="crf0010" refid="s0010"><ce:bold>132</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0015"><ce:para id="p0015"><ce:bold>General approach to the poisoned patient</ce:bold> <ce:cross-ref id="crf0015" refid="s0025"><ce:bold>134</ce:bold></ce:cross-ref><ce:list id="ulist0015"><ce:list-item id="u0020"><ce:para id="p0020">Triage and resuscitation <ce:cross-ref id="crf0020" refid="s0030">134</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0025"><ce:para id="p0025">Clinical assessment and investigations <ce:cross-ref id="crf0025" refid="s0035">134</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0030"><ce:para id="p0030">Psychiatric assessment <ce:cross-ref id="crf0030" refid="s0040">135</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0035"><ce:para id="p0035">General management <ce:cross-ref id="crf0035" refid="s0045">135</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0040"><ce:para id="p0040"><ce:bold>Poisoning by specific pharmaceutical agents</ce:bold> <ce:cross-ref id="crf0040" refid="s0095"><ce:bold>137</ce:bold></ce:cross-ref><ce:list id="ulist0020"><ce:list-item id="u0045"><ce:para id="p0045">Analgesics <ce:cross-ref id="crf0045" refid="s0100">137</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0050"><ce:para id="p0050">Antidepressants <ce:cross-ref id="crf0050" refid="s0145">138</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0055"><ce:para id="p0055">Cardiovascular medications <ce:cross-ref id="crf0055" refid="s0190">140</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0060"><ce:para id="p0060">Iron <ce:cross-ref id="crf0060" refid="s0235">140</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0065"><ce:para id="p0065">Antipsychotic drugs <ce:cross-ref id="crf0065" refid="s0255">141</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0070"><ce:para id="p0070">Antidiabetic agents <ce:cross-ref id="crf0070" refid="s0275">141</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0075"><ce:para id="p0075">Pharmaceutical agents less commonly taken in poisoning <ce:cross-ref id="crf0075" refid="s0295">141</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0080"><ce:para id="p0080"><ce:bold>Drugs of misuse</ce:bold> <ce:cross-ref id="crf0080" refid="s0300"><ce:bold>141</ce:bold></ce:cross-ref><ce:list id="ulist0025"><ce:list-item id="u0085"><ce:para id="p0085">Depressants <ce:cross-ref id="crf0085" refid="s0305">141</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0090"><ce:para id="p0090">Stimulants and entactogens <ce:cross-ref id="crf0090" refid="s0325">143</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0095"><ce:para id="p0095">Hallucinogens <ce:cross-ref id="crf0095" refid="s0340">143</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0100"><ce:para id="p0100">Dissociative drugs <ce:cross-ref id="crf0100" refid="s0365">144</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0105"><ce:para id="p0105">Volatile substances <ce:cross-ref id="crf0105" refid="s0370">144</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0110"><ce:para id="p0110">Body packers and body stuffers <ce:cross-ref id="crf0110" refid="s0375">144</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0115"><ce:para id="p0115"><ce:bold>Chemicals and pesticides</ce:bold> <ce:cross-ref id="crf0115" refid="s0380"><ce:bold>144</ce:bold></ce:cross-ref><ce:list id="ulist0030"><ce:list-item id="u0120"><ce:para id="p0120">Carbon monoxide <ce:cross-ref id="crf0120" refid="s0385">144</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0125"><ce:para id="p0125">Organophosphorus insecticides and nerve agents <ce:cross-ref id="crf0125" refid="s0400">145</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0130"><ce:para id="p0130">Carbamate insecticides <ce:cross-ref id="crf0130" refid="s0435">146</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0135"><ce:para id="p0135">Paraquat <ce:cross-ref id="crf0135" refid="s0440">147</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0140"><ce:para id="p0140">Methanol and ethylene glycol <ce:cross-ref id="crf0140" refid="s0445">147</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0145"><ce:para id="p0145">Corrosive substances <ce:cross-ref id="crf0145" refid="s0465">147</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0150"><ce:para id="p0150">Aluminium and zinc phosphide <ce:cross-ref id="crf0150" refid="s0470">148</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0155"><ce:para id="p0155">Copper sulphate <ce:cross-ref id="crf0155" refid="s0475">148</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0160"><ce:para id="p0160">Chemicals less commonly taken in poisoning <ce:cross-ref id="crf0160" refid="s0480">148</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0165"><ce:para id="p0165">Chemical warfare agents <ce:cross-ref id="crf0165" refid="s0485">149</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0170"><ce:para id="p0170"><ce:bold>Environmental poisoning</ce:bold> <ce:cross-ref id="crf0170" refid="s0490"><ce:bold>149</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0175"><ce:para id="p0175"><ce:bold>Food-related poisoning</ce:bold> <ce:cross-ref id="crf0175" refid="s0545"><ce:bold>149</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0180"><ce:para id="p0180"><ce:bold>Plant poisoning</ce:bold> <ce:cross-ref id="crf0180" refid="s0570"><ce:bold>150</ce:bold></ce:cross-ref></ce:para></ce:list-item></ce:list></outline><ce:sections><ce:section id="s0010"><ce:section-title id="st0010">Comprehensive evaluation of the poisoned patient</ce:section-title><ce:para id="p0185"><ce:display><ce:figure id="f0010"><ce:alt-text id="atte0290" role="short">Unlabelled image</ce:alt-text><ce:source>Insets (Self-cutting) From Douglas G, Nicol F, Robertson C (eds). Macleod's Clinical examination, 11th edn. Churchill Livingstone, Elsevier Ltd; 2005. (Chemical burn) <ce:inter-ref id="iw0010" xlink:href="http://www.firewiki.net">www.firewiki.net</ce:inter-ref>. (Needle tracks) <ce:inter-ref id="iw0015" xlink:href="http://www.deep6inc.com">www.deep6inc.com</ce:inter-ref>. (Pinpoint pupil) <ce:inter-ref id="iw0020" xlink:href="http://drugrecognition.com/images">http://drugrecognition.com/images</ce:inter-ref>. (Injected conjunctiva) <ce:inter-ref id="iw0025" xlink:href="http://knol.google.com">http://knol.google.com</ce:inter-ref>.</ce:source><ce:link id="ln0010" locator="u007-001-9780702070280" xlink:href="pii:B978070207028000007X/u007-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display><ce:display><ce:textbox id="b0010" role="alt1"><ce:alt-text id="atte0295" role="short">Unlabelled box</ce:alt-text><ce:textbox-head><ce:title id="tit0015"><ce:inline-figure baseline="0.0"><ce:link id="ln9000" locator="icon01-9780702070280" xlink:href="pii:B978070207028000007X/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0300" role="short">Image 19</ce:alt-text></ce:inline-figure>Taking a history in poisoning</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0190"><ce:list id="ulist0035"><ce:list-item id="u0185"><ce:label>•</ce:label><ce:para id="p0195">What toxin(s) have been taken and how much?</ce:para></ce:list-item><ce:list-item id="u0190"><ce:label>•</ce:label><ce:para id="p0200">What time were they taken and by what route?</ce:para></ce:list-item><ce:list-item id="u0195"><ce:label>•</ce:label><ce:para id="p0205">Has alcohol or any other substance (or substances, including drugs of misuse) been taken as well?</ce:para></ce:list-item><ce:list-item id="u0200"><ce:label>•</ce:label><ce:para id="p0210">Obtain details from witnesses (e.g. family, friends, ambulance personnel) of the circumstances of the overdose</ce:para></ce:list-item><ce:list-item id="u0205"><ce:label>•</ce:label><ce:para id="p0215">Assess immediate suicide risk in those with apparent self-harm (full psychiatric evaluation when patient has recovered physically)</ce:para></ce:list-item><ce:list-item id="u0210"><ce:label>•</ce:label><ce:para id="p0220">Assess capacity to make decisions about accepting or refusing treatment</ce:para></ce:list-item><ce:list-item id="u0215"><ce:label>•</ce:label><ce:para id="p0225">Establish past medical history, drug history and allergies, social and family history</ce:para></ce:list-item><ce:list-item id="u0220"><ce:label>•</ce:label><ce:para id="p0230">Record all information carefully</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display><ce:display><ce:figure id="f0015"><ce:caption id="ca0010"><ce:simple-para id="sp0010" role="title">Clinical signs of poisoning by pharmaceutical agents and drugs of misuse.</ce:simple-para></ce:caption><ce:alt-text id="atte0305" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0015" locator="u007-002-9780702070280" xlink:href="pii:B978070207028000007X/u007-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display><ce:display><ce:figure id="f0020"><ce:caption id="ca0015"><ce:simple-para id="sp0015" role="title">Decontamination and enhanced elimination.</ce:simple-para><ce:simple-para id="sp9005" role="caption">One of the key aspects in the evaluation of a poisoned patient is deciding if decontamination and/or enhanced elimination is required.</ce:simple-para></ce:caption><ce:alt-text id="atte0310" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0020" locator="u007-003-9780702070280" xlink:href="pii:B978070207028000007X/u007-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display>Acute poisoning is common, accounting for about 1% of hospital admissions in the UK. Common or otherwise important substances involved are shown in <ce:cross-ref id="crf0185" refid="b0015">Box 7.1</ce:cross-ref><ce:float-anchor refid="b0015"/>. In developed countries, the most frequent cause is intentional drug overdose in the context of self-harm, often involving prescribed or ‘over-the-counter’ medicines. Accidental poisoning is also common, especially in children and the elderly (<ce:cross-ref id="crf0190" refid="b0020">Box 7.2</ce:cross-ref><ce:float-anchor refid="b0020"/>). Toxicity also results from alcohol or recreational substance use, or following occupational or environmental exposure. Poisoning is a major cause of death in young adults, but most deaths occur before patients reach medical attention, and mortality is low (&#x003C; 1%) in those admitted to hospital.</ce:para><ce:para id="p0325">In developing countries, the frequency of self-harm is more difficult to estimate. Because of their widespread availability and use, household and agricultural products, such as pesticides and herbicides, are common sources of poisoning and have a much higher case fatality. In China and South-east Asia, pesticides account for about 300 000 suicides each year. Snake bite and other forms of envenomation are also important causes of morbidity and mortality internationally and are discussed in <ce:intra-ref id="ii0015" xlink:href="pii:B978-0-7020-7028-0.00008-1#c00008">Chapter 8</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0025"><ce:section-title id="st0025">General approach to the poisoned patient</ce:section-title><ce:para id="p0330">A general approach is shown on <ce:cross-ref id="crf9025" refid="s0010">pages 132–133</ce:cross-ref>. In many countries, poisons centres are available to provide advice on management of suspected poisoning with specific substances. Information is also available online (<ce:cross-ref id="crf9030" refid="s0565">p. 150</ce:cross-ref>).</ce:para><ce:section id="s0030"><ce:section-title id="st0030">Triage and resuscitation</ce:section-title><ce:para id="p0335">Patients who are seriously poisoned must be identified early so that appropriate management is not delayed. Triage involves:<ce:list id="ulist0055"><ce:list-item id="u0295"><ce:label>•</ce:label><ce:para id="p0340">immediately assessing vital signs</ce:para></ce:list-item><ce:list-item id="u0300"><ce:label>•</ce:label><ce:para id="p0345">identifying the poison(s) involved and obtaining adequate information about them</ce:para></ce:list-item><ce:list-item id="u0305"><ce:label>•</ce:label><ce:para id="p0350">identifying patients at risk of further attempts at self-harm and removing any remaining hazards.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0355">Those with possible external contamination with chemical or environmental toxins should undergo appropriate decontamination (<ce:cross-ref id="crf9035" refid="f0015">p. 133</ce:cross-ref>). Critically ill patients must be resuscitated (<ce:intra-ref id="ii0035" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0010">p. 174</ce:intra-ref>).</ce:para><ce:para id="p0360">The Glasgow Coma Scale (GCS) is commonly employed to assess conscious level, although not specifically validated in poisoning. The AVPU (alert/verbal/painful/unresponsive) scale is also a rapid and simple method. An electrocardiogram (ECG) should be performed and cardiac monitoring instituted in all patients with cardiovascular features or where exposure to potentially cardiotoxic substances is suspected. Patients who may need antidotes should be weighed if possible, so that appropriate weight-related doses can be prescribed.</ce:para><ce:para id="p0365">Substances unlikely to be toxic in humans should be identified so that inappropriate admission and intervention are avoided (<ce:cross-ref id="crf0195" refid="b0025">Box 7.3</ce:cross-ref><ce:float-anchor refid="b0025"/>).</ce:para></ce:section><ce:section id="s0035"><ce:section-title id="st0035">Clinical assessment and investigations</ce:section-title><ce:para id="p0400">History and examination are described on <ce:cross-ref id="crf9040" refid="s0010">page 132</ce:cross-ref>. Occasionally, patients may be unaware of or confused about what they have taken, or may exaggerate (or, less commonly, underestimate) the size of the overdose, but rarely mislead medical staff deliberately. In regions of the world where self-poisoning is illegal, patients may be reticent about giving a history.</ce:para><ce:para id="p0405">Toxic causes of abnormal physical signs are shown on <ce:cross-ref id="crf9045" refid="f0015">page 133</ce:cross-ref>. The patient may have a cluster of clinical features (‘toxidrome’) suggestive of poisoning with a particular drug type, e.g. anticholinergic, serotoninergic (see <ce:cross-ref id="crf0200" refid="b0060">Box 7.10</ce:cross-ref>), stimulant, sedative, opioid (see <ce:cross-ref id="crf0205" refid="b0070">Box 7.12</ce:cross-ref>) or cholinergic (see <ce:cross-ref id="crf0210" refid="b0080">Box 7.14</ce:cross-ref>) feature clusters. Poisoning is a common cause of coma, especially in younger people, but it is important to exclude other potential causes (<ce:intra-ref id="ii0050" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0425">p. 194</ce:intra-ref>).</ce:para><ce:para id="p0410">Urea, electrolytes and creatinine should be measured in all patients with suspected systemic poisoning. Arterial blood gases should be checked in those with significant respiratory or circulatory compromise, or after poisoning with substances likely to affect acid–base status (<ce:cross-ref id="crf0215" refid="b0030">Box 7.4</ce:cross-ref><ce:float-anchor refid="b0030"/>). Calculation of anion and osmolar gaps may help to inform diagnosis and management (<ce:cross-ref id="crf0225" refid="b0035">Box 7.5</ce:cross-ref><ce:float-anchor refid="b0035"/>). Potent oxidising agents may cause methaemoglobinaemia, with consequent blue discoloration of skin and blood, and reduced oxygen delivery to the tissues (<ce:cross-ref id="crf0240" refid="f0025">Fig. 7.1</ce:cross-ref><ce:float-anchor refid="f0025"/>).</ce:para><ce:para id="p0530">For some substances, management may be facilitated by measurement of the amount of toxin in the blood. Qualitative urine screens for potential toxins, including near-patient testing kits, have a limited clinical role.</ce:para></ce:section><ce:section id="s0040"><ce:section-title id="st0040">Psychiatric assessment</ce:section-title><ce:para id="p0535">Patients presenting with drug overdose in the context of self-harm should undergo psychiatric evaluation prior to discharge by a health professional with appropriate training (<ce:intra-ref id="ii0065" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0370">p. 1187</ce:intra-ref>). This should occur after they have recovered from poisoning, unless there is an urgent issue, such as uncertainty about their capacity to decline medical treatment.</ce:para></ce:section><ce:section id="s0045"><ce:section-title id="st0045">General management</ce:section-title><ce:para id="p0540">Patients presenting with eye/skin contamination should undergo local decontamination measures. These are described on<ce:cross-ref id="crf9050" refid="f0015">page 133</ce:cross-ref>.</ce:para><ce:section id="s0050"><ce:section-title id="st0050">Gastrointestinal decontamination</ce:section-title><ce:para id="p0545">Patients who have ingested potentially life-threatening quantities of toxins may be considered for gastrointestinal decontamination if poisoning has been recent (<ce:cross-ref id="crf9055" refid="f0015">p. 133</ce:cross-ref>).</ce:para><ce:section id="s0055"><ce:section-title id="st0055">Activated charcoal</ce:section-title><ce:para id="p0550">Given orally as a slurry, activated charcoal absorbs toxins in the bowel as a result of its large surface area. It can prevent absorption of an important proportion of the ingested dose of toxin, but efficacy decreases with time and current guidelines do not encourage use more than 1 hour after overdose, unless a sustained-release preparation has been taken or when gastric emptying may be delayed. Use is ineffective for some toxins that do not bind to activated charcoal (<ce:cross-ref id="crf0245" refid="b0040">Box 7.6</ce:cross-ref><ce:float-anchor refid="b0040"/>). In patients with impaired swallowing or a reduced level of consciousness, activated charcoal, even via a nasogastric tube, carries a risk of aspiration pneumonitis, which can be reduced (but not eliminated) by protecting the airway with a cuffed endotracheal tube.</ce:para><ce:para id="p0605">Multiple doses of oral activated charcoal (50 g 6 times daily in an adult) may enhance the elimination of some substances at any time after poisoning (<ce:cross-ref id="crf0265" refid="b0045">Box 7.7</ce:cross-ref><ce:float-anchor refid="b0045"/>). This interrupts enterohepatic circulation or reduces the concentration of free drug in the gut lumen, to the extent that drug diffuses from the blood back into the bowel to be absorbed on to the charcoal (‘gastrointestinal dialysis’). A laxative is generally given with the charcoal to reduce the risk of constipation or intestinal obstruction by charcoal ‘briquette’ formation in the gut lumen.</ce:para><ce:para id="p0695">Evidence suggests that single or multiple doses of activated charcoal do not improve clinical outcomes after poisoning with pesticides or oleander.</ce:para></ce:section><ce:section id="s0060"><ce:section-title id="st0060">Gastric aspiration and lavage</ce:section-title><ce:para id="p0700">Gastric aspiration and/or lavage is very infrequently indicated in acute poisoning, as it is no more effective than activated charcoal for most substances and complications are common, especially pulmonary aspiration. It is contraindicated if strong acids, alkalis or petroleum distillates have been ingested. Use may be justified for life-threatening overdoses of those substances that are not absorbed by activated charcoal (see <ce:cross-ref id="crf0270" refid="b0040">Box 7.6</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0065"><ce:section-title id="st0065">Whole bowel irrigation</ce:section-title><ce:para id="p0705">This involves the administration of large quantities of osmotically balanced polyethylene glycol and electrolyte solution (1–2 L/hr for an adult), usually by a nasogastric tube, until the rectal effluent is clear. It is occasionally indicated to enhance the elimination of ingested packets of illicit drugs or slow-release tablets such as iron and lithium that are not absorbed by activated charcoal. Contraindications include inadequate airway protection, haemodynamic instability, gastrointestinal haemorrhage, obstruction or ileus. Whole bowel irrigation may precipitate nausea and vomiting, abdominal pain and electrolyte disturbances.</ce:para></ce:section></ce:section><ce:section id="s0070"><ce:section-title id="st0070">Urinary alkalinisation</ce:section-title><ce:para id="p0710">Urinary excretion of weak acids and bases is affected by urinary pH, which changes the extent to which they are ionised. Highly ionised molecules pass poorly through lipid membranes and therefore little tubular reabsorption occurs and urinary excretion is increased. If the urine is alkalinised (pH &#x003E; 7.5) by the administration of sodium bicarbonate (e.g. 1.5 L of 1.26% sodium bicarbonate over 2 hrs), weak acids (e.g. salicylates, methotrexate) are highly ionised, resulting in enhanced urinary excretion.</ce:para><ce:para id="p0715">Urinary alkalinisation is currently recommended for patients with clinically significant salicylate poisoning when the criteria for haemodialysis are not met (see below). It is also sometimes used for poisoning with methotrexate. Complications include alkalaemia, hypokalaemia and occasionally alkalotic tetany (<ce:intra-ref id="ii0080" xlink:href="pii:B978-0-7020-7028-0.00014-7#p2365">p. 367</ce:intra-ref>). Hypocalcaemia may occur but is rare.</ce:para></ce:section><ce:section id="s0075"><ce:section-title id="st0075">Haemodialysis and haemoperfusion</ce:section-title><ce:para id="p0720">These techniques can enhance the elimination of poisons that have a small volume of distribution and a long half-life after overdose; use is appropriate when poisoning is sufficiently severe. The toxin must be small enough to cross the dialysis membrane (haemodialysis) or must bind to activated charcoal (haemoperfusion) (see <ce:cross-ref id="crf0275" refid="b0045">Box 7.7</ce:cross-ref>). Haemodialysis can also correct acid–base and metabolic disturbances associated with poisoning (<ce:cross-ref id="crf9060" refid="s0040">p. 135</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0080"><ce:section-title id="st0080">Lipid emulsion therapy</ce:section-title><ce:para id="p0725">Lipid emulsion therapy is increasingly used for poisoning with lipid-soluble agents, such as local anaesthetics, tricyclic antidepressants, calcium channel blockers and lipid-soluble β-adrenoceptor antagonists (β-blockers) such as propranolol. It involves intravenous infusion of 20% lipid emulsion (e.g. Intralipid, suggested initial dose 1.5 mL/kg, followed by a continued infusion of 0.25 mL/kg/min until there is clinical improvement). It is thought that lipid-soluble toxins partition into the intravenous lipid, reducing target tissue concentrations. The elevated myocardial free fatty acid concentrations may also have beneficial effects on myocardial metabolism and performance by counteracting the inhibition of myocardial fatty acid oxidation produced by some cardiotoxins, enabling increased adenosine triphosphate (ATP) synthesis and energy production. Some animal studies have suggested efficacy and case reports of use in human poisoning have also been encouraging, with recovery of circulatory collapse reported in cases where other treatment modalities have been unsuccessful. No controlled trials of this technique have been performed, however, and efficacy remains uncertain.</ce:para></ce:section><ce:section id="s0085"><ce:section-title id="st0085">Supportive care</ce:section-title><ce:para id="p0730">For most poisons, antidotes and methods to accelerate elimination are inappropriate, unavailable or incompletely effective. Outcome is dependent on appropriate nursing and supportive care, and treatment of complications (<ce:cross-ref id="crf0280" refid="b0050">Box 7.8</ce:cross-ref><ce:float-anchor refid="b0050"/>).</ce:para></ce:section><ce:section id="s0090"><ce:section-title id="st0090">Antidotes</ce:section-title><ce:para id="p0905">Antidotes are available for some poisons and work by a variety of mechanisms (<ce:cross-ref id="crf0285" refid="b0055">Box 7.9</ce:cross-ref><ce:float-anchor refid="b0055"/>). The use of some of these in the management of specific poisons is described below.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0095"><ce:section-title id="st0095">Poisoning by specific pharmaceutical agents</ce:section-title><ce:section id="s0100"><ce:section-title id="st0100">Analgesics</ce:section-title><ce:section id="s0105"><ce:section-title id="st0105">Paracetamol</ce:section-title><ce:para id="p0915">Paracetamol (acetaminophen) is the drug most commonly used in overdose in the UK. Toxicity is caused by an intermediate reactive metabolite that binds covalently to cellular proteins, causing cell death. This results in hepatic and occasionally renal failure. In therapeutic doses, the toxic metabolite is detoxified in reactions requiring glutathione, but in overdose, glutathione reserves become exhausted.</ce:para><ce:section id="s0110"><ce:section-title id="st0110">Management</ce:section-title><ce:para id="p0920">Activated charcoal may be used in patients presenting within 1 hour. Antidotes for paracetamol act by replenishing hepatic glutathione and should be administered to all patients with acute poisoning and paracetamol concentrations above a ‘treatment line’ provided on paracetamol poisoning nomograms (<ce:cross-ref id="crf0290" refid="f0030">Fig. 7.2</ce:cross-ref><ce:float-anchor refid="f0030"/>). The threshold used for these nomograms varies between countries, however, and local guidance should be followed. Acetylcysteine given intravenously (or orally in some countries) is highly efficacious if administered within 8 hours of the overdose. However, efficacy declines thereafter, so administration should not be delayed in patients presenting after 8 hours to await a paracetamol blood concentration result. The antidote can be stopped if the paracetamol concentration is shown to be below the nomogram treatment line. Liver and renal function, International Normalised Ratio (INR) and a venous bicarbonate should also be measured. Arterial blood gases and lactate should be assessed in patients with reduced bicarbonate or severe liver function abnormalities; metabolic acidosis indicates severe poisoning.</ce:para><ce:para id="p0925">Anaphylactoid reactions are the most important adverse effects of acetylcysteine and are related to dose-related histamine release. Common features are itching and urticaria, and in severe cases, bronchospasm and hypotension. Most cases can be managed by temporary discontinuation of acetylcysteine and administration of an antihistamine.</ce:para><ce:para id="p0930">An alternative antidote is methionine 2.5 g orally (adult dose) every 4 hours to a total of four doses, but this may be less effective, especially after delayed presentation. Liver transplantation should be considered for paracetamol poisoning with life-threatening liver failure (<ce:intra-ref id="ii0100" xlink:href="pii:B978-0-7020-7028-0.00022-6#s0225">p. 856</ce:intra-ref>).</ce:para><ce:para id="p0935">If multiple ingestions of paracetamol have taken place over several hours (‘staggered overdose’) or days (e.g. chronic therapeutic excess), acetylcysteine may be indicated; specific treatment recommendations vary between countries.</ce:para></ce:section></ce:section><ce:section id="s0115"><ce:section-title id="st0115">Salicylates (aspirin)</ce:section-title><ce:section id="s0120"><ce:section-title id="st0120">Clinical features</ce:section-title><ce:para id="p0940">Salicylate overdose commonly causes nausea, vomiting, sweating, tinnitus and deafness. Direct stimulation of the respiratory centre produces hyperventilation and respiratory alkalosis. Peripheral vasodilatation with bounding pulses and profuse sweating occurs in moderately severe cases. Serious poisoning is associated with metabolic acidosis, hypoprothrombinaemia, hyperglycaemia, hyperpyrexia, renal failure, pulmonary oedema, shock and cerebral oedema. Agitation, delirium, coma and fits may occur, especially in children. Toxicity is enhanced by acidosis, which increases salicylate transfer across the blood–brain barrier.</ce:para></ce:section><ce:section id="s0125"><ce:section-title id="st0125">Management</ce:section-title><ce:para id="p0945">Activated charcoal should be administered if the patient presents within 1 hour. Multiple doses may enhance salicylate elimination but are not routinely recommended.</ce:para><ce:para id="p0950">The plasma salicylate concentration should be measured at least 2 (symptomatic patients) or 4 hours (asymptomatic patients) after overdose and repeated in suspected serious poisoning, as concentrations may continue to rise for several hours. Clinical status, however, is more important than the salicylate concentration when assessing severity.</ce:para><ce:para id="p0955">Dehydration should be corrected carefully because of the risk of pulmonary oedema. Metabolic acidosis should be treated with intravenous sodium bicarbonate (8.4%), after plasma potassium has been corrected. Urinary alkalinisation is indicated for adults with salicylate concentrations above 500 mg/L.</ce:para><ce:para id="p0960">Haemodialysis is very effective for removing salicylate and correcting associated acid–base and fluid balance abnormalities. It should be considered when serum concentrations are above 700 mg/L in adults with severe toxic features, or in renal failure, pulmonary oedema, coma, convulsions or refractory acidosis.</ce:para></ce:section></ce:section><ce:section id="s0130"><ce:section-title id="st0130">Non-steroidal anti-inflammatory drugs</ce:section-title><ce:section id="s0135"><ce:section-title id="st0135">Clinical features</ce:section-title><ce:para id="p0965">Overdose of most non-steroidal anti-inflammatory drugs (NSAIDs) usually causes only minor abdominal discomfort, vomiting and/or diarrhoea, but convulsions can occur occasionally, especially with mefenamic acid. Coma, prolonged seizures, apnoea, liver dysfunction and renal failure may follow substantial overdose but are rare. Features of toxicity are unlikely to develop in patients who are asymptomatic more than 6 hours after overdose.</ce:para></ce:section><ce:section id="s0140"><ce:section-title id="st0140">Management</ce:section-title><ce:para id="p0970">Electrolytes, liver function tests and a full blood count should be checked in all but the most trivial cases. Activated charcoal may be given if the patient presents within 1 hour. Symptomatic treatment for nausea and gastrointestinal irritation may be needed.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0145"><ce:section-title id="st0145">Antidepressants</ce:section-title><ce:section id="s0150"><ce:section-title id="st0150">Tricyclic antidepressants</ce:section-title><ce:para id="p0975">Overdose with tricyclic antidepressants (TCAs) carries a high morbidity and mortality because of their sodium channel-blocking, anticholinergic and α-adrenoceptor-blocking effects.</ce:para><ce:section id="s0155"><ce:section-title id="st0155">Clinical features</ce:section-title><ce:para id="p0980">Anticholinergic effects are common (<ce:cross-ref id="crf0295" refid="b0060">Box 7.10</ce:cross-ref><ce:float-anchor refid="b0060"/>). Severe complications include convulsions, coma and arrhythmias (ventricular tachycardia, ventricular fibrillation and, less commonly, heart block). Hypotension results from inappropriate vasodilatation or impaired myocardial contractility. Serious complications appear more common with dosulepin and amitriptyline.</ce:para></ce:section><ce:section id="s0160"><ce:section-title id="st0160">Management</ce:section-title><ce:para id="p1090">Activated charcoal should be administered if the patient presents within 1 hour. A 12-lead ECG should be taken and continuous cardiac monitoring maintained for at least 6 hours. Prolongation of the QRS interval (especially if &#x003E; 0.16 secs) indicates severe sodium channel blockade and a high risk of arrhythmia (<ce:cross-ref id="crf0305" refid="f0035">Fig. 7.3</ce:cross-ref><ce:float-anchor refid="f0035"/>). QT interval prolongation may also occur. Arterial blood gases should be measured in suspected severe poisoning.</ce:para><ce:para id="p1095">In patients with arrhythmias, significant QRS or QT prolongation or acidosis, intravenous sodium bicarbonate (50 mL of 8.4% solution) should be administered and repeated to correct pH. The correction of the acidosis and the sodium loading that results may bring about rapid improvement in ECG features and arrhythmias. Hypoxia and electrolyte abnormalities should also be corrected. Anti-arrhythmic drugs should only be given on specialist advice. Prolonged seizures should be treated initially with intravenous benzodiazepines (see <ce:cross-ref id="crf0310" refid="b0050">Box 7.8</ce:cross-ref>).</ce:para></ce:section></ce:section><ce:section id="s0165"><ce:section-title id="st0165">Selective serotonin and noradrenaline re-uptake inhibitors</ce:section-title><ce:para id="p1100">Selective serotonin re-uptake inhibitor (SSRI) antidepressants (e.g. fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram) are increasingly used to treat depression and are less toxic in overdose than TCAs. The related serotonin–noradrenaline re-uptake inhibitors (SNRIs), such as venlafaxine and duloxetine, are also commonly used but are more toxic than SSRIs in overdose.</ce:para><ce:section id="s0170"><ce:section-title id="st0170">Clinical features and management</ce:section-title><ce:para id="p1105">Overdose of SSRIs may produce nausea and vomiting, tremor, insomnia and sinus tachycardia. Agitation, drowsiness and convulsions occur infrequently and may be delayed for several hours. Serotonin syndrome may occur (see <ce:cross-ref id="crf0315" refid="b0060">Box 7.10</ce:cross-ref>), especially if SSRIs are taken in combination or with other serotonergic agents. Cardiac arrhythmias occur infrequently and most patients require supportive care only. The toxic effects of SNRIs are similar but tachycardia, hypertension or hypotension and ECG changes (QRS and QT prolongation) may be more prominent and hypoglycaemia can also arise.</ce:para></ce:section></ce:section><ce:section id="s0175"><ce:section-title id="st0175">Lithium</ce:section-title><ce:para id="p1110">Severe lithium toxicity is uncommon after intentional acute overdose but is more often encountered in patients taking therapeutic doses, frequently as a result of interactions with drugs such as diuretics or NSAIDs. Severe toxicity is more common after acute overdose in patients already taking chronic therapy (‘acute on chronic’ poisoning).</ce:para><ce:section id="s0180"><ce:section-title id="st0180">Clinical features</ce:section-title><ce:para id="p1115">Nausea, diarrhoea, polyuria, dizziness and tremor may progress to muscular weakness, drowsiness, delirium, myoclonus, fasciculations, choreoathetosis and renal failure. Coma, seizures, ataxia, cardiac dysrhythmias such as heart block, blood pressure disturbances and renal failure may occur in severe poisoning.</ce:para></ce:section><ce:section id="s0185"><ce:section-title id="st0185">Management</ce:section-title><ce:para id="p1120">Activated charcoal is ineffective. Early gastric lavage is of theoretical benefit, but lithium tablets are likely to remain intact in the stomach and may be too large for aspiration via a lavage tube. Whole bowel irrigation is often used after substantial overdose but efficacy is unproven.</ce:para><ce:para id="p1125">Lithium concentrations should be measured immediately (symptomatic patients) or after at least 6 hours (asymptomatic patients) following acute overdose. The usual therapeutic range is 0.4–1.0 mmol/L. Adequate hydration should be maintained with intravenous fluids. Seizures should be treated as in <ce:cross-ref id="crf0320" refid="b0050">Box 7.8</ce:cross-ref>.</ce:para><ce:para id="p1130">Haemodialysis should be considered for severe toxicity associated with high lithium concentrations (e.g. &#x003E; 4.0 mmol/L after chronic or ‘acute on chronic’ poisoning, or &#x003E; 7.5 mmol/L after acute poisoning). Lithium concentrations are reduced substantially during dialysis, but rebound increases occur after discontinuation and multiple sessions are usually required.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0190"><ce:section-title id="st0190">Cardiovascular medications</ce:section-title><ce:para id="p1135">Although not common, cardiovascular drug overdose is important because features of toxicity are often severe.</ce:para><ce:section id="s0195"><ce:section-title id="st0195">Beta-blockers</ce:section-title><ce:para id="p1140">Major features of toxicity are bradycardia and hypotension; heart block, pulmonary oedema and cardiogenic shock occur in severe poisoning. Those with additional sodium channel-blocking effects (e.g. propranolol, acebutolol, carvedilol) may cause seizures, delirium and coma, while sotalol, which also blocks potassium channels, may cause QT<ce:inf loc="post">c</ce:inf> prolongation and torsades de pointes (<ce:cross-ref id="crf0325" refid="b0050">Box 7.8</ce:cross-ref> and <ce:intra-ref id="ii0105" xlink:href="pii:B978-0-7020-7028-0.00016-0#s0830">p. 476</ce:intra-ref>).</ce:para><ce:section id="s0200"><ce:section-title id="st0200">Management</ce:section-title><ce:para id="p1145">Intravenous fluids may reverse hypotension but care is required to avoid pulmonary oedema. Bradycardia and hypotension may respond to high doses of atropine (up to 3 mg in an adult) or an infusion of isoproterenol. Glucagon (5–10 mg over 10 mins, then 1–5 mg/hr by infusion) counteracts β-blockade by stimulating intracellular cyclic adenosine monophosphate (cAMP) production and is now more commonly used. In severe cases, ‘hyperinsulinaemia euglycaemic therapy’ has been used, as described under calcium channel blockers below. The efficacy of lipid emulsion therapy in severe poisoning with lipid-soluble β-blockers, such as propranolol, carvedilol and oxprenolol, is uncertain.</ce:para></ce:section></ce:section><ce:section id="s0205"><ce:section-title id="st0205">Calcium channel blockers</ce:section-title><ce:para id="p1150">L-type calcium channel blockers are highly toxic in overdose. Dihydropyridines (e.g. nifedipine, amlodipine) cause vasodilatation, whereas diltiazem and verapamil have predominantly cardiac effects, including bradycardia and reduced myocardial contractility.</ce:para><ce:section id="s0210"><ce:section-title id="st0210">Clinical features</ce:section-title><ce:para id="p1155">Hypotension due to vasodilatation or myocardial depression is common and bradycardias and heart block may also occur, especially with verapamil and diltiazem. Gastrointestinal disturbances, delirium, metabolic acidosis, hyperglycaemia and hyperkalaemia may also be present.</ce:para></ce:section><ce:section id="s0215"><ce:section-title id="st0215">Management</ce:section-title><ce:para id="p1160">Hypotension should be corrected with intravenous fluids, taking care to avoid pulmonary oedema. Persistent hypotension may respond to intravenous calcium gluconate (10 mg IV over 5 mins, repeated as required). Isoproterenol and glucagon may also be useful. Successful use of intravenous insulin with glucose (10–20% dextrose with insulin initially at 0.5–2.0 U/kg/hr, increasing to 5–10 U/kg/hr according to clinical response), so-called ‘hyperinsulinaemia euglycaemic therapy’, has been reported in patients unresponsive to other strategies. The mechanism of action remains to be fully elucidated, but in states of shock myocardial metabolism switches from use of free fatty acids to glucose. Calcium channel blocker poisoning is also associated with hypoinsulinaemia and insulin resistance, impeding glucose uptake by myocytes. High doses of insulin inhibit lipolysis and increase glucose uptake and the efficiency of glucose utilisation. Cardiac pacing may be needed for severe unresponsive bradycardias or heart block. Lipid emulsion therapy has also been used in severe poisoning with apparent benefit, although evidence is largely anecdotal.</ce:para></ce:section></ce:section><ce:section id="s0220"><ce:section-title id="st0220">Digoxin and oleander</ce:section-title><ce:para id="p1165">Poisoning with digoxin is usually accidental, arising from prescription of an excessive dose, impairment of renal function or drug interactions. In South Asia, deliberate self-poisoning with yellow oleander (<ce:italic>Thevetia peruviana</ce:italic>), containing cardiac glycosides, is common.</ce:para><ce:section id="s0225"><ce:section-title id="st0225">Clinical features</ce:section-title><ce:para id="p1170">Cardiac effects include tachyarrhythmias (either atrial or ventricular) and bradycardias, with or without atrioventricular block. Ventricular bigeminy is common and atrial tachycardia with evidence of atrioventricular block is highly suggestive of the diagnosis. Severe poisoning is often associated with hyperkalaemia. Non-cardiac features include delirium, headache, nausea, vomiting, diarrhoea and (rarely) altered colour vision. Digoxin poisoning can be confirmed by elevated plasma concentration (usual therapeutic range 1.3–2.5 mmol/L). After chronic exposure, concentrations &#x003E; 5 mmol/L suggest serious poisoning.</ce:para></ce:section><ce:section id="s0230"><ce:section-title id="st0230">Management</ce:section-title><ce:para id="p1175">Activated charcoal is commonly administered to patients presenting soon after acute ingestion, although evidence of benefit is lacking. Urea, electrolytes and creatinine should be measured, a 12-lead ECG performed and cardiac monitoring instituted. Hypoxia, hypokalaemia (sometimes caused by concurrent diuretic use), hypomagnesaemia and acidosis increase the risk of arrhythmias and should be corrected. Significant bradycardias may respond to atropine, although temporary pacing is sometimes needed. Ventricular arrhythmias may respond to intravenous magnesium (see <ce:cross-ref id="crf0330" refid="b0050">Box 7.8</ce:cross-ref>). If available, digoxin-specific antibody fragments should be administered when there are severe refractory ventricular arrhythmias or bradycardias. These are effective for both digoxin and yellow oleander poisoning.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0235"><ce:section-title id="st0235">Iron</ce:section-title><ce:para id="p1180">Overdose with iron can cause severe and sometimes fatal poisoning, with toxicity of individual iron preparations related to their elemental iron content.</ce:para><ce:section id="s0240"><ce:section id="s0245"><ce:section-title id="st0240">Clinical features</ce:section-title><ce:para id="p1185">Early features include gastrointestinal disturbance with the passage of grey or black stools, progressing to hyperglycaemia, leucocytosis, haematemesis, rectal bleeding, drowsiness, convulsions, coma, metabolic acidosis and cardiovascular collapse in severe cases. Early symptoms may improve or resolve within 6–12 hours, but hepatocellular necrosis can develop 12–24 hours after overdose and occasionally progresses to hepatic failure. Gastrointestinal strictures are late complications.</ce:para></ce:section><ce:section id="s0250"><ce:section-title id="st0245">Management</ce:section-title><ce:para id="p1195">Activated charcoal is ineffective but gastric lavage may be considered in patients presenting soon after substantial overdose, although efficacy is unknown. Serum iron concentration should be measured at least 4 hours after overdose or earlier if there are features of toxicity. Desferrioxamine chelates iron and should be administered immediately in patients with severe features, without waiting for serum iron concentrations, as well as symptomatic patients with high serum iron concentrations (e.g. &#x003E; 5 mg/L). Desferrioxamine may cause hypotension, allergic reactions and occasionally pulmonary oedema. Otherwise, treatment is supportive and directed at complications.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0255"><ce:section-title id="st0250">Antipsychotic drugs</ce:section-title><ce:para id="p1200">Antipsychotic drugs (<ce:intra-ref id="ii0110" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0785">p. 1198</ce:intra-ref>) are often prescribed for patients at high risk of self-harm or suicide and are often taken in overdose.</ce:para><ce:section id="s0260"><ce:section id="s0265"><ce:section-title id="st0255">Clinical features</ce:section-title><ce:para id="p1205">Anticholinergic features (see <ce:cross-ref id="crf0335" refid="b0060">Box 7.10</ce:cross-ref>) including drowsiness, tachycardia and hypotension, are common and convulsions may occur. Acute dystonias, including oculogyric crisis, torticollis and trismus, may occur after overdose with typical antipsychotics like haloperidol or chlorpromazine. QT interval prolongation and torsades de pointes can occur with some typical (e.g. haloperidol) and atypical (e.g. quetiapine, amisulpride, ziprasidone) agents.</ce:para></ce:section><ce:section id="s0270"><ce:section-title id="st0260">Management</ce:section-title><ce:para id="p1210">Activated charcoal may be of benefit if given early. Cardiac monitoring should be undertaken for at least 6 hours. Management is largely supportive, with treatment directed at complications (see <ce:cross-ref id="crf0340" refid="b0050">Box 7.8</ce:cross-ref>).</ce:para></ce:section></ce:section></ce:section><ce:section id="s0275"><ce:section-title id="st0265">Antidiabetic agents</ce:section-title><ce:para id="p1215">Overdose is uncommon but toxic effects can be severe.</ce:para><ce:section id="s0280"><ce:section id="s0285"><ce:section-title id="st0270">Clinical features</ce:section-title><ce:para id="p1220">Sulphonylureas, meglitinides (e.g. nateglinide, repaglinide) and parenteral insulin cause hypoglycaemia when taken in overdose, although insulin is non-toxic if ingested by mouth. The duration of hypoglycaemia depends on the half-life or release characteristics of the preparation and may be prolonged over several days with long-acting agents such as glibenclamide, insulin zinc suspension or insulin glargine.</ce:para><ce:para id="p1225">Features of hypoglycaemia include nausea, agitation, sweating, aggression, delirium, tachycardia, hypothermia, drowsiness, convulsions and coma (<ce:intra-ref id="ii0115" xlink:href="pii:B978-0-7020-7028-0.00020-2#s0375">p. 738</ce:intra-ref>). Permanent neurological damage can occur if hypoglycaemia is prolonged. Hypoglycaemia can be diagnosed using bedside glucose strips but venous blood should also be sent for laboratory confirmation.</ce:para><ce:para id="p1230">Metformin is uncommonly associated with hypoglycaemia. Its major toxic effect is lactic acidosis, which can have a high mortality, and is particularly common in older patients and those with renal or hepatic impairment, or when ethanol has been co-ingested. Other features of metformin overdose are nausea, vomiting, diarrhoea, abdominal pain, drowsiness, coma, hypotension and cardiovascular collapse.</ce:para><ce:para id="p1235">There is limited experience of overdose involving thiazolidinediones (e.g. pioglitazone) and dipeptidyl peptidase 4 (DPP-4) inhibitors (e.g. sitagliptin) but significant hypoglycaemia is unlikely.</ce:para></ce:section><ce:section id="s0290"><ce:section-title id="st0275">Management</ce:section-title><ce:para id="p1240">Activated charcoal should be considered for recent substantial overdose. Venous blood glucose and urea and electrolytes should be measured and measurement repeated regularly. Hypoglycaemia should be corrected using oral or intravenous glucose (50 mL of 50% dextrose); an infusion of 10–20% dextrose may be required to prevent recurrence. Intramuscular glucagon can be used as an alternative, especially if intravenous access is unavailable. Failure to regain consciousness within a few minutes of normalisation of the blood glucose can indicate that a central nervous system (CNS) depressant has also been ingested, the hypoglycaemia has been prolonged, or there is another cause of coma (e.g. cerebral haemorrhage or oedema).</ce:para><ce:para id="p1245">Arterial blood gases and plasma lactate should be taken after metformin overdose; acidosis should be corrected with intravenous sodium bicarbonate (250 mL 1.26% solution or 50 mL 8.4% solution, repeated as necessary). In severe cases, haemodialysis or haemodiafiltration is used.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0295"><ce:section-title id="st0280">Pharmaceutical agents less commonly taken in poisoning</ce:section-title><ce:para id="p1250">An overview of the clinical features and management for drugs less commonly involved in poisoning is provided in <ce:cross-ref id="crf0345" refid="b0065">Box 7.11</ce:cross-ref><ce:float-anchor refid="b0065"/>.</ce:para></ce:section></ce:section><ce:section id="s0300"><ce:section-title id="st0285">Drugs of misuse</ce:section-title><ce:para id="p1390">Drugs of misuse are common causes of toxicity requiring hospital admission. Management has recently become more complex because of the emergence of ‘novel psychoactive substances’ (NPS). These are often chemically related to traditional drugs of misuse, but with structural modifications made to evade legal control. The constituents of branded NPS products are often unknown and knowledge about the clinical features and management of NPS toxicity is limited.</ce:para><ce:section id="s0305"><ce:section-title id="st0290">Depressants</ce:section-title><ce:para id="p1395">These produce CNS depression, including drowsiness, ataxia, delirium and coma, sometimes with respiratory depression, airway compromise, aspiration pneumonia and respiratory arrest (<ce:cross-ref id="crf0350" refid="b0070">Box 7.12</ce:cross-ref><ce:float-anchor refid="b0070"/>). Other complications of coma include pressure blisters or sores and rhabdomyolysis. Effects are potentiated by other CNS depressants, including alcohol.</ce:para><ce:para id="p1580">Essential supportive care is detailed in <ce:cross-ref id="crf0390" refid="b0050">Box 7.8</ce:cross-ref>. Antidotes are available for some depressants.</ce:para><ce:section id="s0310"><ce:section-title id="st0295">Benzodiazepines</ce:section-title><ce:para id="p1585">Benzodiazepines (e.g. diazepam) and related substances (e.g. zopiclone) are of low toxicity when taken alone in overdose but can enhance CNS and respiratory depression when taken with other sedative agents, including alcohol. They are more hazardous in the elderly and those with chronic lung or neuromuscular disease (see <ce:cross-ref id="crf0395" refid="b0070">Box 7.12</ce:cross-ref>).</ce:para><ce:para id="p1590">The specific benzodiazepine antagonist flumazenil (0.5 mg IV, repeated if needed) increases conscious level in patients with benzodiazepine overdose, but carries a risk of seizures and is contraindicated in patients co-ingesting pro-convulsants (e.g. TCAs) and those with a history of epilepsy.</ce:para></ce:section><ce:section id="s0315"><ce:section-title id="st0300">Opioids</ce:section-title><ce:para id="p1595">Toxicity may result from misuse of illicit drugs such as heroin or from intentional or accidental overdose of medicinal opiates. Intravenous or smoked heroin gives a rapid, intensely pleasurable experience, often accompanied by heightened sexual arousal. Physical dependence occurs within a few weeks of regular high-dose use. Withdrawal can start within 12 hours, causing intense craving, rhinorrhoea, lacrimation, yawning, perspiration, shivering, piloerection, vomiting, diarrhoea and abdominal cramps. Examination reveals tachycardia, hypertension, mydriasis and facial flushing.</ce:para><ce:para id="p1600">Commonly encountered opioids and clinical features of poisoning are shown in <ce:cross-ref id="crf0400" refid="b0070">Box 7.12</ce:cross-ref>. Needle tracks may be visible in intravenous users and there may be drug-related paraphernalia. Methadone may also cause QT<ce:inf loc="post">c</ce:inf> prolongation and torsades de pointes. Features of opioid poisoning can be prolonged for up to 48 hours after use of long-acting agents such as methadone or oxycodone.</ce:para><ce:para id="p1605">Use of the specific opioid antagonist naloxone (0.4–2 mg IV in an adult, repeated if necessary) may obviate the need for intubation, although excessive doses may precipitate acute withdrawal in chronic opiate users and breakthrough pain in those receiving opioids for pain management. Repeated doses or an infusion are often required because the half-life of the antidote is short compared to that of most opiates, especially those with prolonged elimination. Patients should be monitored for at least 6 hours after the last naloxone dose. Rare complications of naloxone therapy include fits, ventricular arrhythmias and pulmonary oedema.</ce:para></ce:section><ce:section id="s0320"><ce:section-title id="st0305">Gamma hydroxybutyrate</ce:section-title><ce:para id="p1610">Gamma hydroxybutyrate (GHB), and the related compounds gamma butyrolactone (GBL) and 1,4 butanediol are sedative liquids with psychedelic and body-building effects.</ce:para><ce:para id="p1615">As well as sedative hypnotic features (see <ce:cross-ref id="crf0405" refid="b0070">Box 7.12</ce:cross-ref>), toxicity may cause nausea, diarrhoea, vertigo, tremor, myoclonus, extrapyramidal signs, euphoria, bradycardia, convulsions, metabolic acidosis, hypokalaemia and hyperglycaemia. Coma usually resolves abruptly within a few hours but occasionally persists for several days. Dependence may develop in regular users, who experience severe, prolonged withdrawal effects if use is discontinued suddenly.</ce:para><ce:para id="p1620">Management is largely supportive. All patients should be observed for a minimum of 2 hours and until symptoms resolve, with monitoring of blood pressure, heart rate, respiratory rate and oxygenation. Withdrawal symptoms may require treatment with very high doses of benzodiazepine.</ce:para></ce:section></ce:section><ce:section id="s0325"><ce:section-title id="st0310">Stimulants and entactogens</ce:section-title><ce:para id="p1625">These are sympathomimetic and serotonergic amines that have overlapping clinical features, depending on the balance of their stimulant (see <ce:cross-ref id="crf0410" refid="b0070">Box 7.12</ce:cross-ref>) and serotonergic (see <ce:cross-ref id="crf0415" refid="b0060">Box 7.10</ce:cross-ref>) effects. As well as traditional drugs such as cocaine, amphetamines and ecstasy, the group includes many more recently emerging novel psychoactive substances, including cathinones (e.g. mephedrone), piperazines (e.g. benzylpiperazine), piperadines (e.g. ethylphenidate), benzofurans (e.g. 5-aminopropylbenzofuran) and NBOMe compounds (e.g. 25I-NBOMe).</ce:para><ce:section id="s0330"><ce:section-title id="st0315">Cocaine</ce:section-title><ce:para id="p1630">Cocaine is available as a water-soluble hydrochloride salt powder suitable for nasal inhalation (‘snorting’), or as insoluble free-base (‘crack’ cocaine) ‘rocks’ that, unlike the hydrochloride salt, vaporise at high temperature and can be smoked, giving a more rapid and intense effect.</ce:para><ce:para id="p1635">Effects appear rapidly after inhalation and especially after smoking. Sympathomimetic stimulant effects predominate (see <ce:cross-ref id="crf0420" refid="b0070">Box 7.12</ce:cross-ref>). Serious complications usually occur within 3 hours of use and include coronary artery spasm, leading to myocardial ischaemia or infarction, hypotension and ventricular arrhythmias. Cocaine toxicity should be considered in younger adults presenting with ischaemic chest pain. Hyperpyrexia, rhabdomyolysis, acute renal failure and disseminated intravascular coagulation may occur.</ce:para><ce:para id="p1640">A 12-lead ECG and ECG monitoring should be undertaken. ST segment elevation may occur in the absence of myocardial infarction and troponin T estimations are the most sensitive and specific markers of myocardial damage. Benzodiazepines and intravenous nitrates are useful for managing patients with chest pain or hypertension. Acidosis should be corrected and physical cooling measures used for hyperthermia. Beta-blockers may be contraindicated because of the risk of unopposed α-adrenoceptor stimulation, but this is debated. Coronary angiography should be considered in patients with myocardial infarction or acute coronary syndromes.</ce:para></ce:section><ce:section id="s0335"><ce:section-title id="st0320">Amphetamines and cathinones</ce:section-title><ce:para id="p1645">Amphetamine-related compounds include amphetamine sulphate (‘speed’), methylamphetamine (‘crystal meth’) and 3,4-methylene-dioxymethamphetamine (MDMA, ‘ecstasy’). Synthetic cathinones include mephedrone and methylenedioxypyrovalerone. Tolerance is common, leading regular users to seek ever higher doses.</ce:para><ce:para id="p1650">Toxic features usually appear within a few minutes of use and last 4–6 hours, or substantially longer after a large overdose. Sympathomimetic stimulant and serotonergic effects are common (see <ce:cross-ref id="crf0425" refid="b0060">Boxes 7.10</ce:cross-ref> and <ce:cross-ref id="crf0430" refid="b0070">7.12</ce:cross-ref>). Some users develop hyponatraemia as a result of excessive water-drinking or inappropriate vasopressin (antidiuretic hormone, ADH) secretion. Muscle rigidity, pain and bruxism (clenching of the jaw), hyperpyrexia, rhabdomyolysis, metabolic acidosis, acute renal failure, disseminated intravascular coagulation, hepatocellular necrosis, acute respiratory distress syndrome (ARDS) and cardiovascular collapse have all been described following MDMA use. Cerebral infarction and haemorrhage have been reported, especially after intravenous amphetamine use.</ce:para><ce:para id="p1655">Management is supportive and directed at complications (see <ce:cross-ref id="crf0435" refid="b0050">Box 7.8</ce:cross-ref>).</ce:para></ce:section></ce:section><ce:section id="s0340"><ce:section-title id="st0325">Hallucinogens</ce:section-title><ce:section id="s0345"><ce:section-title id="st0330">Cannabis</ce:section-title><ce:para id="p1660">Derived from the dried leaves and flowers of <ce:italic>Cannabis sativa</ce:italic>, cannabis produces euphoria, perceptual alterations and conjunctival injection, followed by enhanced appetite, relaxation and occasionally hypertension, tachycardia, slurred speech and ataxia. Effects occur 10–30 minutes after smoking or 1–3 hours after ingestion, and last 4–8 hours. High doses may produce anxiety, delirium, hallucinations and psychosis. Psychological dependence is common, but tolerance and withdrawal symptoms are unusual. Long-term use is thought to increase the lifetime risk of psychosis. Serious acute toxicity is uncommon and supportive treatment is all that is required.</ce:para></ce:section><ce:section id="s0350"><ce:section-title id="st0335">Synthetic cannabinoid receptor agonists</ce:section-title><ce:para id="p1665">Large numbers of synthetic cannabinoid receptor agonists (SCRAs), synthetic compounds sometimes referred to collectively as ‘spice’, are now used as legal alternatives to cannabis; examples include PB-22, 5F-PB-22, 5F-AKB-48, STS-135, SF-ADB and MDMB-CHMICA. They are usually sprayed on to a herbal smoking mix and packaged as smoking products with appealing brand names. These may contain more than one SCRA and content may change with time.</ce:para><ce:para id="p1670">The toxic effects of SCRAs differ from those of cannabis, being generally more marked and including agitation, panic, delirium, hallucinations, tachycardia, ECG changes, hypertonia, dyspnoea and vomiting. Coma, respiratory acidosis, seizures, hypokalaemia and renal dysfunction are also reported. Treatment of intoxication is supportive.</ce:para></ce:section><ce:section id="s0355"><ce:section-title id="st0340">Tryptamines</ce:section-title><ce:para id="p1675">These are predominantly 5-hydroxytryptamine (5-HT, serotonin; especially 5-HT2a) agonists with associated stimulant effects. Typical clinical features include hallucinations, agitation, delirium, hypertension, tachycardia, sweating, anxiety and headache. Serotonin syndrome may occur (see <ce:cross-ref id="crf0440" refid="b0060">Box 7.10</ce:cross-ref>), especially if tryptamines are used in combination with other serotonergic agents. Naturally occurring examples are psilocin and psilocybin, found in ‘magic mushrooms’, and dimethyltryptamine (DMT) in traditional ayahuasca brews. Synthetic tryptamines, such as alpha-methyltryptamine (AMT), have been encountered recently.</ce:para></ce:section><ce:section id="s0360"><ce:section-title id="st0345"><ce:italic>d</ce:italic>-Lysergic acid diethylamide</ce:section-title><ce:para id="p1680"><ce:italic>d</ce:italic>-Lysergic acid diethylamide (LSD) is a synthetic ergoline usually ingested as small squares of impregnated absorbent paper (often printed with a distinctive design) or as ‘microdots’. The drug causes perceptual effects, such as heightened visual awareness of colours or distortion of images. Hallucinations may be pleasurable or terrifying (‘bad trip’). Other features are delirium, agitation, aggression, dilated pupils, hypertension, pyrexia and metabolic acidosis. Psychosis may sometimes last several days.</ce:para><ce:para id="p1685">Patients with psychotic reactions or CNS depression should be observed in hospital, preferably in a quiet, dimly lit room to minimise external stimulation. A benzodiazepine that can be used for sedation is required, avoiding antipsychotics if possible, as they may precipitate cardiovascular collapse or convulsions.</ce:para></ce:section></ce:section><ce:section id="s0365"><ce:section-title id="st0350">Dissociative drugs</ce:section-title><ce:para id="p1690">Ketamine, its <ce:italic>N</ce:italic>-ethyl derivative methoxetamine and phencyclidine (now rarely encountered) produce a sense of dissociation from reality, often associated with visual and auditory distortions. Memory loss, impaired consciousness, agitation, hallucinations, tremors and numbness may also occur. Long-term ketamine (and probably methoxetamine) use can cause severe chronic cystitis with dysuria, frequency, urgency, haematuria and incontinence. Treatment of intoxication is supportive.</ce:para></ce:section><ce:section id="s0370"><ce:section-title id="st0355">Volatile substances</ce:section-title><ce:para id="p1695">Inhalation of volatile nitrites (e.g. amyl nitrite, isobutyl nitrite), often sold in bottles or vials as ‘poppers’, is reported to produce a feeling of pleasure and warmth, relax the anal sphincter and prolong orgasm. These potent vasodilators commonly provoke headache, dizziness, hypotension and tachycardia. They also oxidise haemoglobin to produce methaemoglobinaemia, with resulting breathlessness and delirium. Severe cases are treated with methylthioninium chloride (‘methylene blue’, see <ce:cross-ref id="crf0445" refid="f0025">Fig 7.1</ce:cross-ref>).</ce:para><ce:para id="p1700">Several volatile solvents found in household products, such as propane, butane, toluene and trichloroethylene, have a mild euphoriant effect if inhaled. Serious toxic effects can occur, including reduced level of consciousness, seizures and cardiac arrhythmias; there is also a risk of asphyxia from some methods of inhalation.</ce:para><ce:para id="p1705">Nitrous oxide is an anaesthetic gas, but small canisters of it are sold for the domestic production of whipped cream and the contents of these can be transferred to balloons for inhalation. The gas has euphoriant effects (‘laughing gas’), but hazards include asphyxia from inhalation without oxygen, or vitamin B<ce:inf loc="post">12</ce:inf> inactivation from chronic use leading to megaloblastic anaemia, psychosis and other neurological sequelae.</ce:para></ce:section><ce:section id="s0375"><ce:section-title id="st0360">Body packers and body stuffers</ce:section-title><ce:para id="p1710">Body packers (‘mules’) attempt to smuggle illicit drugs (usually cocaine, heroin or amphetamines) by ingesting multiple small packages wrapped in several layers of clingfilm or in condoms. Body stuffers are those who have ingested unpackaged or poorly wrapped substances, often to avoid arrest. Both groups are at risk of severe toxicity if the packages rupture. This is more likely for body stuffers, who may develop symptoms of poisoning within 8 hours of ingestion. The risk of poisoning depends on the quality of the wrapping, and the amount and type of drug ingested. Cocaine, for example, presents a much higher risk than heroin because of its high toxicity and lack of a specific antidote.</ce:para><ce:para id="p1715">Patients suspected of body packing or stuffing should be admitted for observation. A careful history taken in private is important, but for obvious reasons patients may withhold details of the drugs involved. The mouth, rectum and vagina should be examined as possible sites for concealed drugs. A urine toxicology screen performed at intervals may provide evidence of leakage, although positive results may reflect earlier drug use. Packages may be visible on plain abdominal films (<ce:cross-ref id="crf0450" refid="f0040">Fig. 7.4</ce:cross-ref><ce:float-anchor refid="f0040"/>) but ultrasound and computed tomography (CT) are more sensitive. One of these (preferably CT) should be performed in all suspected body packers.</ce:para><ce:para id="p1720">Antimotility agents are often used by body packers to prevent premature passage of packages; it can take several days for packages to pass spontaneously, during which the carrier is at risk from package rupture. Whole bowel irrigation is commonly used to accelerate passage and is continued until all packages have passed. Surgery may be required when there is mechanical bowel obstruction or when evolving clinical features suggest package rupture, especially with cocaine.</ce:para></ce:section></ce:section><ce:section id="s0380"><ce:section-title id="st0365">Chemicals and pesticides</ce:section-title><ce:section id="s0385"><ce:section-title id="st0370">Carbon monoxide</ce:section-title><ce:para id="p1725">Carbon monoxide (CO) is a colourless, odourless gas produced by faulty appliances burning organic fuels. It is also present in vehicle exhaust fumes and sometimes in smoke from house fires. It binds with haemoglobin and cytochrome oxidase, reducing tissue oxygen delivery and inhibiting cellular respiration. CO is a common cause of death by poisoning and most patients die before reaching hospital.</ce:para><ce:section id="s0390"><ce:section-title id="st0375">Clinical features</ce:section-title><ce:para id="p1730">Early features include headache, nausea, irritability, weakness and tachypnoea. The cause of these non-specific features may not be obvious if the exposure is occult, such as from a faulty domestic appliance. Subsequently, ataxia, nystagmus, drowsiness and hyper-reflexia may develop, progressing to coma, convulsions, hypotension, respiratory depression, cardiovascular collapse and death. Myocardial ischaemia may result in arrhythmias or myocardial infarction. Cerebral oedema is common and rhabdomyolysis may cause myoglobinuria and renal failure. In those who recover from acute toxicity, longer-term neuropsychiatric effects are common, such as personality change, memory loss and concentration impairment. Extrapyramidal effects, urinary or faecal incontinence, and gait disturbance may also occur. Poisoning during pregnancy may cause fetal hypoxia and intrauterine death.</ce:para></ce:section><ce:section id="s0395"><ce:section-title id="st0380">Management</ce:section-title><ce:para id="p1735">Patients should be removed from exposure as soon as possible and resuscitated as necessary. A high concentration of oxygen should be administered via a tightly fitting facemask; this reduces the half-life of carboxyhaemoglobin from 4–6 hours to about 40 minutes. Measurement of carboxyhaemoglobin is useful for confirming exposure; levels &#x003E; 20% suggest significant exposure but do not correlate well with the severity of poisoning, partly because concentrations fall rapidly after removal of the patient from exposure, especially if supplemental oxygen has been given.</ce:para><ce:para id="p1740">An ECG should be performed in all patients with acute CO poisoning, especially those with pre-existing heart disease. Arterial blood gas analysis should be checked in those with serious poisoning. Pulse oximetry may provide misleading oxygen saturations because carboxyhaemoglobin and oxyhaemoglobin are both measured. Excessive intravenous fluid administration should be avoided, particularly in the elderly, because of the risk of pulmonary and cerebral oedema. Convulsions should be controlled with diazepam.</ce:para><ce:para id="p1745">Hyperbaric oxygen therapy is controversial. At 2.5 atmospheres, this reduces the half-life of carboxyhaemoglobin to about 20 minutes and increases the amount of oxygen dissolved in plasma 10-fold, but systematic reviews have not consistently shown improved clinical outcomes. The logistical difficulties of transporting sick patients to hyperbaric chambers and managing them therein are substantial.</ce:para></ce:section></ce:section><ce:section id="s0400"><ce:section-title id="st0385">Organophosphorus insecticides and nerve agents</ce:section-title><ce:para id="p1750">Organophosphorus (OP) compounds (<ce:cross-ref id="crf0455" refid="b0075">Box 7.13</ce:cross-ref><ce:float-anchor refid="b0075"/>) are widely used as pesticides, especially in developing countries. Case fatality following deliberate ingestion is high (5–20%).</ce:para><ce:para id="p1810">Nerve agents, developed for chemical warfare, are derived from OP insecticides and are much more toxic. They are commonly classified as G (originally synthesised in Germany) or V (‘venomous’) agents. The ‘G’ agents, such as tabun, sarin and soman, are volatile, absorbed by inhalation or via the skin, and dissipate rapidly after use. ‘V’ agents, such as VX, are contact poisons unless aerosolised, and contaminate ground for weeks or months.</ce:para><ce:para id="p1815">The toxicology and management of nerve agent and pesticide poisoning are similar.</ce:para><ce:section id="s0405"><ce:section-title id="st0390">Mechanism of toxicity</ce:section-title><ce:para id="p1820">OP compounds inactivate acetylcholinesterase (AChE), resulting in the accumulation of acetylcholine (ACh) in cholinergic synapses (<ce:cross-ref id="crf0460" refid="f0045">Fig. 7.5</ce:cross-ref><ce:float-anchor refid="f0045"/>). Initially, spontaneous hydrolysis of the OP–enzyme complex allows reactivation of the enzyme but, subsequently, loss of a chemical group from the OP–enzyme complex prevents further enzyme reactivation. After this process (termed ‘ageing’) has taken place, new enzyme needs to be synthesised before function can be restored. The rate of ‘ageing’ is an important determinant of toxicity and is more rapid with dimethyl (3.7 hrs) than diethyl (31 hrs) compounds (<ce:cross-ref id="crf0465" refid="b0075">Box 7.13</ce:cross-ref>) and especially rapid after exposure to nerve agents (soman in particular), which cause ‘ageing’ within minutes.</ce:para></ce:section><ce:section id="s0410"><ce:section-title id="st0395">Clinical features and management</ce:section-title><ce:para id="p1825">OP poisoning causes an acute cholinergic phase, which may occasionally be followed by the intermediate syndrome or organophosphate-induced delayed polyneuropathy (OPIDN). The onset, severity and duration of poisoning depend on the route of exposure and agent involved.</ce:para><ce:section id="s0415"><ce:section-title id="st0400">Acute cholinergic syndrome</ce:section-title><ce:para id="p1830">This usually starts within a few minutes of exposure and nicotinic or muscarinic features may be present (<ce:cross-ref id="crf0470" refid="b0080">Box 7.14</ce:cross-ref><ce:float-anchor refid="b0080"/>). Vomiting and profuse diarrhoea are typical following ingestion. Bronchoconstriction, bronchorrhoea and salivation may cause severe respiratory compromise. Excess sweating and miosis are characteristic and the presence of muscular fasciculations strongly suggests the diagnosis, although this feature is often absent, even in serious poisoning. Subsequently, generalised flaccid paralysis may develop and affect respiratory and ocular muscles, resulting in respiratory failure. Ataxia, coma, convulsions, cardiac repolarisation abnormalities and torsades de pointes may occur.</ce:para><ce:section id="s0420"><ce:section-title id="st0405">Management</ce:section-title><ce:para id="p1840">The airway should be cleared of excessive secretions, breathing and circulation assessed, high-flow oxygen administered and intravenous access obtained. Appropriate external decontamination is needed (<ce:cross-ref id="crf9065" refid="f0015">p. 133</ce:cross-ref>). Gastric lavage or activated charcoal may be considered if the patient presents sufficiently early. Seizures should be treated as described in <ce:cross-ref id="crf0480" refid="b0050">Box 7.8</ce:cross-ref>. The ECG, oxygen saturation, blood gases, temperature, urea and electrolytes, amylase and glucose should be monitored closely.</ce:para><ce:para id="p1845">Early use of sufficient doses of atropine is potentially life-saving in patients with severe toxicity. Atropine reverses ACh-induced bronchospasm, bronchorrhoea, bradycardia and hypotension. When the diagnosis is uncertain, a marked increase in heart rate associated with skin flushing after a 1 mg intravenous dose makes OP poisoning unlikely. In OP poisoning, atropine (2 mg IV) should be administered and this dose should be doubled every 5–10 minutes until clinical improvement occurs. Further bolus doses should be given until secretions are controlled, the skin is dry, blood pressure is adequate and heart rate is &#x003E; 80 bpm. Large doses may be needed, but excessive doses may cause anticholinergic effects (see <ce:cross-ref id="crf0485" refid="b0060">Box 7.10</ce:cross-ref>).</ce:para><ce:para id="p1850">In severe poisoning requiring atropine, an oxime such as pralidoxime chloride or obidoxime is generally recommended, if available, although efficacy is debated. This may reverse or prevent muscle weakness, convulsions or coma, especially if given rapidly after exposure. Oximes reactivate AChE that has not undergone ‘ageing’ and are therefore less effective with dimethyl compounds and nerve agents, especially soman. Oximes may provoke hypotension, especially if administered rapidly.</ce:para><ce:para id="p1855">Intravenous magnesium sulphate has been reported to increase survival in animals and in small human studies of OP poisoning; however, further clinical trial evidence is needed before this can be recommended routinely.</ce:para><ce:para id="p1860">Ventilatory support should be instituted before the patient develops respiratory failure. Benzodiazepines may be used to treat agitation, fasciculations and seizures and for sedation during mechanical ventilation.</ce:para><ce:para id="p1865">Exposure is confirmed by measurement of plasma or red blood cell cholinesterase activity but antidote use should not be delayed pending results. Plasma cholinesterase is reduced more rapidly but is less specific than red cell cholinesterase. Values correlate poorly with the severity of clinical features but are usually &#x003C; 10% in severe poisoning, 20–50% in moderate poisoning and &#x003E; 50% in subclinical poisoning.</ce:para><ce:para id="p1870">The acute cholinergic phase usually lasts 48–72 hours, with most patients requiring intensive cardiorespiratory support and monitoring. Cholinergic features may be prolonged over several weeks with some lipid-soluble agents.</ce:para></ce:section></ce:section><ce:section id="s0425"><ce:section-title id="st0410">Intermediate syndrome</ce:section-title><ce:para id="p1875">About 20% of patients with OP poisoning develop weakness that spreads rapidly from the ocular muscles to those of the head and neck, proximal limbs and the muscles of respiration, resulting in ventilatory failure. This ‘intermediate syndrome’ generally develops 1–4 days after exposure, often after resolution of the acute cholinergic syndrome, and may last 2–3 weeks. There is no specific treatment and supportive care is needed, including maintenance of airway and ventilation.</ce:para></ce:section><ce:section id="s0430"><ce:section-title id="st0415">Organophosphate-induced delayed polyneuropathy</ce:section-title><ce:para id="p1880">Organophosphate-induced delayed polyneuropathy (OPIDN) is a rare complication that usually occurs 2–3 weeks after acute exposure. It is a mixed sensory/motor polyneuropathy, affecting long myelinated neurons especially, and appears to result from inhibition of enzymes other than AChE. It is a feature of poisoning with some OPs such as triorthocresyl phosphate but is less common with nerve agents. Early clinical features are muscle cramps followed by numbness and paraesthesiae, proceeding to flaccid paralysis of the lower and subsequently the upper limbs, with foot and wrist drop and a high-stepping gait, progressing to paraplegia. Sensory loss may also be present but is variable. Initially, tendon reflexes are reduced or lost but mild spasticity may develop later.</ce:para><ce:para id="p1885">There is no specific therapy for OPIDN. Regular physiotherapy may limit deformity caused by muscle-wasting. Recovery is often incomplete and may be limited to the hands and feet, although substantial functional recovery after 1–2 years may occur, especially in younger patients.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0435"><ce:section-title id="st0420">Carbamate insecticides</ce:section-title><ce:para id="p1890">Carbamate insecticides such as bendiocarb, carbofuran, carbaryl and methomyl inhibit a number of tissue esterases, including AChE. The mechanism, clinical features and management of toxicity are similar to those of OP compounds. However, clinical features are usually less severe and of shorter duration, because the carbamate–AChE complex dissociates quickly, with a half-life of 30–40 minutes, and does not undergo ageing. Also, carbamates penetrate the CNS poorly. Intermediate syndrome and OPIDN are not common features of carbamate poisoning. In spite of this, case fatality can be high for some carbamates, depending on their formulation.</ce:para><ce:para id="p1895">Atropine may be given intravenously as for OP poisoning (<ce:cross-ref id="crf9070" refid="s0415">p. 146</ce:cross-ref>). Diazepam may be used to relieve anxiety. The use of oximes is unnecessary.</ce:para></ce:section><ce:section id="s0440"><ce:section-title id="st0425">Paraquat</ce:section-title><ce:para id="p1900">Paraquat is a herbicide that is widely used across the world, although it has been banned in the European Union and some other countries for several years. It is highly toxic if ingested, with clinical features including oral burns, vomiting and diarrhoea, progressing to pneumonitis, pulmonary fibrosis and multi-organ failure.</ce:para><ce:para id="p1905">Exposure can be confirmed by a urinary dithionite test, while the plasma paraquat concentration indicates prognosis. There is no specific antidote but activated charcoal is commonly administered. Immunosuppression with glucocorticoids and cyclophosphamide is sometimes used but evidence for benefit is weak. Irrespective of treatment, death is common and may occur within 24 hours with substantial poisoning or after 1–2 weeks with lower doses.</ce:para></ce:section><ce:section id="s0445"><ce:section-title id="st0430">Methanol and ethylene glycol</ce:section-title><ce:para id="p1910">Ethylene glycol (1,2-ethanediol) is found in antifreeze, brake fluids and, in lower concentrations, windscreen washes. Methanol is present in some antifreeze products and commercially available industrial solvents, and in low concentrations in some screen washes and methylated spirits. It may also be an adulterant of illicitly produced alcohol. Both are rapidly absorbed after ingestion. Methanol and ethylene glycol are not of high intrinsic toxicity but are converted via alcohol dehydrogenase to toxic metabolites that are largely responsible for their clinical effects (<ce:cross-ref id="crf0490" refid="f0050">Fig. 7.6</ce:cross-ref><ce:float-anchor refid="f0050"/>).</ce:para><ce:section id="s0450"><ce:section id="s0455"><ce:section-title id="st0435">Clinical features</ce:section-title><ce:para id="p1915">Early features of poisoning with either methanol or ethylene glycol include vomiting, ataxia, drowsiness, dysarthria and nystagmus. As toxic metabolites are formed, metabolic acidosis, tachypnoea, coma and seizures may develop.</ce:para><ce:para id="p1920">Toxic effects of ethylene glycol include ophthalmoplegia, cranial nerve palsies, hyporeflexia and myoclonus. Renal pain and acute tubular necrosis occur because of renal calcium oxalate precipitation. Hypocalcaemia, hypomagnesaemia and hyperkalaemia are common.</ce:para><ce:para id="p1925">Methanol poisoning causes headache, delirium and vertigo. Visual impairment and photophobia develop, associated with optic disc and retinal oedema and impaired pupil reflexes. Blindness may be permanent, although some recovery may occur over several months. Pancreatitis and abnormal liver function have also been reported.</ce:para></ce:section><ce:section id="s0460"><ce:section-title id="st0440">Management</ce:section-title><ce:para id="p1930">Urea and electrolytes, chloride, bicarbonate, glucose, calcium, magnesium, albumin, plasma osmolarity and arterial blood gases should be measured in all patients with suspected methanol or ethylene glycol toxicity. The osmolar and anion gaps should be calculated (see <ce:cross-ref id="crf0495" refid="b0035">Box 7.5</ce:cross-ref>). Initially, poisoning is associated with an increased osmolar gap, but as toxic metabolites are produced, an increased anion gap develops, associated with metabolic acidosis. The diagnosis can be confirmed by measurement of ethylene glycol or methanol concentrations but assays are not widely available.</ce:para><ce:para id="p1935">An antidote, ideally fomepizole but otherwise ethanol, should be administered to all patients with suspected significant exposure while awaiting the results of laboratory investigations. These block alcohol dehydrogenase and delay the formation of toxic metabolites until the parent drug is eliminated in the urine or by dialysis. The antidote should be continued until ethylene glycol or methanol concentrations are undetectable. Metabolic acidosis should be corrected with sodium bicarbonate (e.g. 250 mL of 1.26% solution, repeated as necessary). Convulsions should be treated with an intravenous benzodiazepine. In ethylene glycol poisoning, hypocalcaemia should be corrected only if there are severe ECG features or if seizures occur, as this may increase calcium oxalate crystal formation. In methanol poisoning, folinic acid should be administered to enhance the metabolism of the toxic metabolite, formic acid.</ce:para><ce:para id="p1940">Haemodialysis or haemodiafiltration should be used in severe poisoning, especially if renal failure is present or there is visual loss in the context of methanol poisoning. It should be continued until acute toxic features are no longer present and ethylene glycol/methanol concentrations are undetectable.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0465"><ce:section-title id="st0445">Corrosive substances</ce:section-title><ce:para id="p1945">Products containing strong acids (e.g. hydrochloric or sulphuric acid) or alkalis (e.g. sodium hydroxide, calcium carbonate) may be ingested, accidentally or intentionally, causing gastrointestinal pain, ulceration and necrosis, with risk of perforation.</ce:para><ce:para id="p1950">External decontamination (<ce:cross-ref id="crf9075" refid="f0015">p. 133</ce:cross-ref>), if needed, should be performed after initial resuscitation. Gastric lavage should not be attempted and neutralising chemicals should not be administered after large ingestions because of the risk of tissue damage from heat release. Cardiorespiratory monitoring is necessary and full blood count, renal function, coagulation and acid–base status should be assessed. An erect chest X-ray should be performed if perforation is suspected and may show features of mediastinitis or gas under the diaphragm. Strong analgesics should be administered for pain.</ce:para><ce:para id="p1955">Severe abdominal or chest pain, abdominal distension, shock or acidosis may indicate perforation and should prompt an urgent CT scan of chest and abdomen and surgical review. In the absence of perforation, drooling, dysphagia, stridor or oropharyngeal burns suggest possible severe oesophageal damage and early endoscopy by an experienced operator should be considered. Delayed endoscopy (e.g. after several days) may carry a higher risk of perforation.</ce:para></ce:section><ce:section id="s0470"><ce:section-title id="st0450">Aluminium and zinc phosphide</ce:section-title><ce:para id="p1960">These rodenticides and fumigants are a common means of self-poisoning in northern India. The mortality rate for aluminium phosphide ingestion has been estimated at 60%; zinc phosphide ingestion appears less toxic, at about 2%. When ingested, both compounds react with gastric acid to form phosphine, a potent pulmonary and gastrointestinal toxicant. Clinical features include severe gastrointestinal disturbances, chest tightness, cough and breathlessness progressing to ARDS and respiratory failure, tremor, paraesthesiae, convulsions, coma, tachycardia, metabolic acidosis, electrolyte disturbances, hypoglycaemia, myocarditis, liver and renal failure, and leucopenia. Ingestion of a few tablets can be fatal.</ce:para><ce:para id="p1965">Treatment is supportive and directed at correcting electrolyte abnormalities and treating complications; there is no specific antidote. Early gastric lavage is sometimes used, often with vegetable oil to reduce the release of toxic phosphine, but the benefit is uncertain.</ce:para></ce:section><ce:section id="s0475"><ce:section-title id="st0455">Copper sulphate</ce:section-title><ce:para id="p1970">This is used as a fungicide. If it is ingested, clinical features of toxicity include nausea, vomiting, abdominal pain, diarrhoea, discoloured (blue/green) secretions, corrosive effects on the gastrointestinal tract, renal or liver failure, methaemoglobinaemia, haemolysis, rhabdomyolysis, convulsions and coma. Treatment is as for other corrosive substances (see above) and should address complications, including use of methylthioninium chloride for methaemoglobinaemia (see <ce:cross-ref id="crf0500" refid="f0025">Fig. 7.1</ce:cross-ref>). Chelation therapy is unlikely to be beneficial after acute exposure.</ce:para></ce:section><ce:section id="s0480"><ce:section-title id="st0460">Chemicals less commonly taken in poisoning</ce:section-title><ce:para id="p1975">An overview of the clinical features and management for chemicals less commonly involved in poisoning is provided in <ce:cross-ref id="crf0505" refid="b0085">Box 7.15</ce:cross-ref><ce:float-anchor refid="b0085"/>.</ce:para></ce:section><ce:section id="s0485"><ce:section-title id="st0465">Chemical warfare agents</ce:section-title><ce:para id="p2190">Some toxins have been developed for use as chemical warfare agents. These are summarised in <ce:cross-ref id="crf0510" refid="b0090">Box 7.16</ce:cross-ref><ce:float-anchor refid="b0090"/>.</ce:para></ce:section></ce:section><ce:section id="s0490"><ce:section-title id="st0470">Environmental poisoning</ce:section-title><ce:section id="s0495"><ce:section id="s0500"><ce:section-title id="st0475">Arsenism</ce:section-title><ce:para id="p2245">Chronic arsenic exposure from drinking water has been reported in many countries, especially India, Bangladesh, Nepal, Thailand, Taiwan, China, Mexico and South America, where a large proportion of the drinking water (ground water) has a high arsenic content, placing large populations at risk. The World Health Organisation (WHO) guideline value for arsenic content in tube well water is 10 µg/L.</ce:para><ce:para id="p2250">Health effects associated with chronic exposure to arsenic in drinking water are shown in <ce:cross-ref id="crf0525" refid="b0095">Box 7.17</ce:cross-ref><ce:float-anchor refid="b0095"/>. In exposed individuals, high concentrations of arsenic are present in bone, hair and nails. Specific treatments are of no benefit in chronic arsenic toxicity and recovery from the peripheral neuropathy may never be complete, so the emphasis should be on prevention.</ce:para></ce:section><ce:section id="s0540"><ce:section-title id="st0515">Fluorosis</ce:section-title><ce:para id="p2325">Fluoride poisoning can result from exposure to excessive quantities of fluoride (&#x003E; 10 ppm) in drinking water, industrial exposure to fluoride dust or consumption of brick teas. Clinical features include yellow staining and pitting of permanent teeth, osteosclerosis, soft tissue calcification, deformities (e.g. kyphosis) and joint ankylosis. Changes in the bones of the thoracic cage may lead to rigidity that causes dyspnoea on exertion. Very high doses of fluoride may cause abdominal pain, nausea, vomiting, seizures and muscle spasm. In calcium-deficient children, the toxic effects of fluoride manifest even at marginally high exposures to fluoride.</ce:para><ce:para id="p2330">In endemic areas, such as Jordan, Turkey, Chile, India, Bangladesh, China and Tibet, fluorosis is a major public health problem, especially in communities engaged in physically strenuous agricultural or industrial activities. Dental fluorosis is endemic in East Africa and some West African countries.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0545"><ce:section-title id="st0520">Food-related poisoning</ce:section-title><ce:section id="s0550"><ce:section id="s0555"><ce:section-title id="st0525">Paralytic shellfish poisoning</ce:section-title><ce:para id="p2335">Paralytic shellfish poisoning is caused by consumption of bivalve molluscs (e.g. mussels, clams, oysters, cockles and scallops) contaminated with saxitoxins, which are concentrated in the shellfish as a result of constant filtration of toxic algae during algal blooms (e.g. ‘red tide’). Symptoms develop within 10–120 minutes of eating the contaminated shellfish and include gastrointestinal disturbances, paraesthesia around the mouth or in the extremities, ataxia, mental state changes and dysphagia. In severe cases, paralysis and respiratory failure can develop. There is no specific antidote and treatment is supportive. Most cases resolve over a few days.</ce:para></ce:section><ce:section id="s0560"><ce:section-title id="st0530">Ciguatera poisoning</ce:section-title><ce:para id="p2340">Ciguatera toxin and related toxins are produced by dinoflagellate plankton that adhere to algae and seaweed. These accumulate in the tropical herbivorous fish that feed on these and in their larger predators (e.g. snapper, barracuda), especially in the Pacific and Caribbean. Human exposure occurs through eating contaminated fish, even if well cooked. Nausea, vomiting, diarrhoea and abdominal pain develop within a few hours, followed by paraesthesia, ataxia, blurred vision, ataxia and tremor. Convulsions and coma can occur, although death is uncommon. Fatigue and peripheral neuropathy can be long-term effects. There is no specific treatment. In the South Pacific and Caribbean, there are approximately 50 000 cases per year, with a case fatality of 0.1%.</ce:para></ce:section><ce:section id="s0565"><ce:section-title id="st0535">Scombrotoxic fish poisoning</ce:section-title><ce:para id="p2345">Under poor storage conditions, histidine in scombroid fish (e.g. tuna, mackerel, bonito, skipjack and the canned dark meat of sardines) may be converted by bacteria to histamine and other chemicals. Within minutes of consumption, flushing, burning, sweating, urticaria, pruritus, headache, colic, nausea and vomiting, diarrhoea, bronchospasm and hypotension may occur. Management is with nebulised salbutamol, intravenous antihistamines and, occasionally, intravenous fluid replacement.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0570"><ce:section-title id="st0540">Plant poisoning</ce:section-title><ce:para id="p2350">A substantial number of plants and fungi are potentially toxic if consumed, with patterns of poisoning depending on their geographical distribution. Some toxic examples and the clinical features of toxicity are shown in <ce:cross-ref id="crf0530" refid="b0100">Box 7.18</ce:cross-ref><ce:float-anchor refid="b0100"/>.</ce:para></ce:section></ce:sections><ce:further-reading id="fr0010"><ce:section-title id="st0545">Further information</ce:section-title><ce:further-reading-sec id="fs0010"><ce:section-title id="st0550">Books and journal articles</ce:section-title><ce:bib-reference id="bib1"><ce:label>Bateman et al, 2014</ce:label><sb:reference id="sr0010"><sb:host><sb:edited-book><sb:editors><sb:editor><ce:given-name>DN</ce:given-name><ce:surname>Bateman</ce:surname></sb:editor><sb:editor><ce:given-name>R</ce:given-name><ce:surname>Jefferson</ce:surname></sb:editor><sb:editor><ce:given-name>SHL</ce:given-name><ce:surname>Thomas</ce:surname></sb:editor><sb:et-al/></sb:editors><sb:title><sb:maintitle>Oxford desk reference: toxicology</sb:maintitle></sb:title><sb:date>2014</sb:date><sb:publisher><sb:name>Oxford University Press</sb:name><sb:location>Oxford</sb:location></sb:publisher></sb:edited-book></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>Benson et al, 2013</ce:label><sb:reference id="sr0015"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>BE</ce:given-name><ce:surname>Benson</ce:surname></sb:author><sb:author><ce:given-name>K</ce:given-name><ce:surname>Hoppu</ce:surname></sb:author><sb:author><ce:given-name>WG</ce:given-name><ce:surname>Troutman</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Position paper update: gastric lavage for gastrointestinal decontamination</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin Toxicol</sb:maintitle></sb:title><sb:volume-nr>51</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>140</sb:first-page><sb:last-page>146</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>Chyka et al, 2005</ce:label><sb:reference id="sr0020"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>PA</ce:given-name><ce:surname>Chyka</ce:surname></sb:author><sb:author><ce:given-name>D</ce:given-name><ce:surname>Seger</ce:surname></sb:author><sb:author><ce:given-name>EP</ce:given-name><ce:surname>Krenzelok</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Position paper: single-dose activated charcoal</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin Toxicol</sb:maintitle></sb:title><sb:volume-nr>43</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>61</sb:first-page><sb:last-page>87</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>Thompson et al, 2014</ce:label><sb:reference id="sr0045"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>JP</ce:given-name><ce:surname>Thompson</ce:surname></sb:author><sb:author><ce:given-name>ID</ce:given-name><ce:surname>Watson</ce:surname></sb:author><sb:author><ce:given-name>HK</ce:given-name><ce:surname>Thanacoody</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Guidelines for laboratory analyses for poisoned patients in the United Kingdom</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Clin Biochem</sb:maintitle></sb:title><sb:volume-nr>51</sb:volume-nr></sb:series><sb:date>2014</sb:date></sb:issue><sb:pages><sb:first-page>312</sb:first-page><sb:last-page>325</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:further-reading-sec><ce:further-reading-sec id="fs0015"><ce:section-title id="st0555">Websites</ce:section-title><ce:bib-reference id="bib9"><ce:label>,</ce:label><sb:reference id="sr0050"><sb:host><sb:e-host><ce:inter-ref id="iw0030" xlink:href="http://curriculum.toxicology.wikispaces.net/" xlink:role="http://www.elsevier.com/xml/linking-roles/research-data">curriculum.toxicology.wikispaces.net/</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0080"><ce:italic>Free access to educational material related to poisoning.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>,</ce:label><sb:reference id="sr0055"><sb:host><sb:e-host><ce:inter-ref id="iw0035" xlink:href="http://toxbase.org" xlink:role="http://www.elsevier.com/xml/linking-roles/research-data">toxbase.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0085"><ce:italic>Toxbase, the clinical toxicology database of the UK National Poisons Information Service. Free for UK health professionals but registration is required. Access for overseas users by special arrangement. Low-cost smartphone app available.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>,</ce:label><sb:reference id="sr0060"><sb:host><sb:e-host><ce:inter-ref id="iw0040" xlink:href="http://toxnet.nlm.nih.gov" xlink:role="http://www.elsevier.com/xml/linking-roles/research-data">toxnet.nlm.nih.gov</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0090"><ce:italic>US National Library of Medicine's Toxnet: a hazardous substances databank, including Toxline for references to literature on drugs and other chemicals.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib18"><ce:label>,</ce:label><sb:reference id="sr0065"><sb:host><sb:e-host><ce:inter-ref id="iw0045" xlink:href="http://who.int/gho/phe/chemical_safety/poisons_centres/en/" xlink:role="http://www.elsevier.com/xml/linking-roles/research-data">who.int/gho/phe/chemical_safety/poisons_centres/en/</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib19"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0095"><ce:italic>World directory of poisons centres held by the WHO, including interactive map and contact details.</ce:italic></ce:simple-para></ce:note></ce:bib-reference></ce:further-reading-sec></ce:further-reading></chapter>